[go: up one dir, main page]

EP1732943A2 - Nouvelles sequences nucelotidiques et d'acides amines, et leurs dosage et procedes d'utilisation pour le diagnostic du cancer du sein - Google Patents

Nouvelles sequences nucelotidiques et d'acides amines, et leurs dosage et procedes d'utilisation pour le diagnostic du cancer du sein

Info

Publication number
EP1732943A2
EP1732943A2 EP05718182A EP05718182A EP1732943A2 EP 1732943 A2 EP1732943 A2 EP 1732943A2 EP 05718182 A EP05718182 A EP 05718182A EP 05718182 A EP05718182 A EP 05718182A EP 1732943 A2 EP1732943 A2 EP 1732943A2
Authority
EP
European Patent Office
Prior art keywords
amino acid
amino acids
homologous
pea
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05718182A
Other languages
German (de)
English (en)
Other versions
EP1732943A4 (fr
Inventor
Amir Toporik
Dvir Dahary
Rotem Sorek
Sarah Pollock
Zurit Levine
Pinchas Akiva
Alexander Diber
Amit Novik
Osnat Sella-Tavor
Michal Ayalon-Sofer
Shira Walach
Shirley Sameah-Greenwald
Ronen Shemesh
Naomi Keren
Maxim Shklar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Compugen USA Inc
Original Assignee
Compugen USA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Compugen USA Inc filed Critical Compugen USA Inc
Priority claimed from PCT/IB2005/000433 external-priority patent/WO2005072050A2/fr
Publication of EP1732943A2 publication Critical patent/EP1732943A2/fr
Publication of EP1732943A4 publication Critical patent/EP1732943A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Definitions

  • the present invention is related to novel nucleotide and protein sequences that are diagnostic markers for breast cancer, and assays and methods of use thereof.
  • Breast cancer is the most commonly occurring cancer in women, comprising almost a third of all malignancies in females. It is the leading cause of death for women between the ages 40-55 in the United States and one out of 8 females in the United States will develop breast cancer at some point in her life. The death rate from breast cancer has been slowly declining over the past decade, partially due do the usage of molecular markers that facilitate the discovery, tumor typing (and therefore choice of treatment), response to treatment and recurrence.
  • the most widely used serum markers for breast cancers are Mucin 1 (measured as CA 15-3) and CEA (CarcinoEmbryonic Antigen). Mucin 1 (MUCl) is present on the apical surface of normal epithelial cells.
  • VNTR Variable Number Tandem Repeat
  • CA 15-3 is a broadly used marker for breast cancer, a combination of CA 15-3 and CEA is more sensitive than using a single marker.
  • CA 15-3, CEA and ESR Epithrocyte Sedimentation Rate
  • Serum markers used to monitor therapeutic response in patients with metastatic breast cancer are associated with the "spike phenomenon". It is an initial transient rise of tumor marker levels which can be seen in up to 30% of responders in the first 3 months of commencing a therapy. It is important not to interpret this as a sign of disease progression leading to premature change of an effective therapy.
  • CA 27.29 is a new monoclonal antibody directed against a different part of MUCl and it is a newer marker than CA 15-3. It detects a different glycosylation pattern of MUCl, as compared with CA 15-3.
  • CA 27.29 is the first FDA- approved blood test for breast cancer recurrence. Because of superior sensitivity and specificity, CA 27.29 has supplanted CA 15-3 as the preferred tumor marker in breast cancer.
  • the CA 27.29 level is elevated in approximately one third of women with early-stage breast cancer (stage I or II) and in two thirds of women with late-stage disease (stage III or IV).
  • CA 27.29 lacks predictive value in the earliest stages of breast cancer and thus has no role in screening for or diagnosing the malignancy.
  • CA 27.29 also can be found in patients with benign disorders of the breast, liver, and kidney, and in patients with ovarian cysts. However, CA 27.29 levels higher than 100 units per mL are rare in benign conditions.
  • Estrogen 2 (beta) was shown to have a diagnostic role in breast cancer. It has been shown that the expression of the 'ex' variant of Estrogen 2 is correlated with response to Hormone adjuvant therapy. In addition it has been shown it may assist in better characterization of ER-1 positive breast cancers (together with progesterone receptor).
  • HER-2 also known as c-erbB2 is a membrane proto-oncogene with intrinsic tyrosine kinase activity.
  • Tumor expressing HER-2 are associated with shorter survival, shorter time-to- relapse and an overall worse prognosis. Tumors expressing HER-2 can be targeted with Trastuzumab - a biological adjuvant therapy which blocks the growth promoting action of HER- 2.
  • the ImmunoHistoChemistry (IHC) and Fluorescence In Situ Hybridization (FISH) tests are used to detect HER2: l.IHC: The most common test used to check HER2 status is an ImmunoHistoChemistry (IHC) test. The IHC test measures the protein made by the HER2 gene. 2. FISH: This test measures the number of copies of the HER2 gene present in the tumor cell.
  • HER-2 has been reported to show a better assessment of response to chemotherapy than a biochemical index score based on measurement of CA 15.3, CEA and ESR in a small series of patient. That finding is yet to be confirmed in a larger group of patient with HER-2 expressing tumors.
  • Other molecular markers mainly used for the diagnosis for cancers other than breast cancer were shown to have a diagnostic potential in breast cancer.
  • CA125 which is a major marker for ovarian cancer is also associated with breast cancer.
  • High levels of CA 19-9 a major marker for colorectal and pancreatic cancers, can be found in breast cancer. Overall, these markers are not frequently used for the detection of breast cancer to due their inferiority compared with other markers already described.
  • markers for the diagnosis and typing of breast cancer are being used by pathologists, including both markers described above and additional markers, such as immunohistochemistry markers that have been shown to have a beneficial value for the diagnosis of breast cancer, including PCNA and Ki-67 are maybe the most important and highly used immunohistochemistry markers for breast cancer.
  • Other markers as E-Cadherin, Cathepsin D and TFF1 are also used for that purpose.
  • Cyclin- E expression level in the breast cancer was found to be a very strong indicator for prognosis, stronger than any other biological marker.
  • pathological conditions which represent an increased risk factor for development breast cancer.
  • Non- limiting examples of these conditions include: - Ductal hyperplasia without atypia. It is the most frequently encountered breast biopsy result that is associated with increased risk of future development of breast cancer (2 fold increased risk).
  • the loss of expression of transforming growth factor beta receptor II in the affected epithelial cells is associated with an increased risk of invasive breast cancer. Atypical hyperplasia.
  • Women having atypical hyperplasia with over-expression of HER-2 have a greater than 7- fold increased risk of developing invasive breast carcinoma, as compared with women with non-proliferative benign breast lesions and no evidence of HER-2 amplification. These pathological conditions should be effectively diagnosed and monitored in order to facilitate early detection of breast cancer.
  • the background art does not teach or suggest markers for breast cancer that are sufficiently sensitive and/or accurate, alone or in combination.
  • the present invention overcomes these deficiencies of the background art by providing novel markers for breast cancer that are both sensitive and accurate. These markers are overexpressed in breast cancer specifically, as opposed to normal breast tissue.
  • the measurement of these markers, alone or in combination, in patient (biological) samples provides information that the diagnostician can correlate with a probable diagnosis of breast cancer.
  • the markers of the present invention alone or in combination, show a high degree of differential detection between breast cancer and non-cancerous states.
  • suitable biological samples which may optionally be used with preferred embodiments of the present invention include but are not limited to blood, serum, plasma, blood cells, urine, sputum, saliva, stool, spinal fluid or CSF, lymph fluid, the external secretions of the skin, respiratory, intestinal, and genitourinary tracts, tears, milk, neuronal tissue, breast tissue, any human organ or tissue, including any tumor or normal tissue, any sample obtained by lavage (for example of the bronchial system or of the breast ductal system), and also samples of in vivo cell culture constituents.
  • the biological sample comprises breast tissue and/or a serum sample and/or a urine sample and/or a milk sample and/or any other tissue or liquid sample.
  • the sample can optionally be diluted with a suitable eluant before contacting the sample to an antibody and/or performing any other diagnostic assay.
  • Information given in the text with regard to cellular localization was determined according to four different software programs: (i) tmhmm (from Center for Biological Sequence Analysis, Technical University of Denmark DTU, http://www.cbs.dm.dk/services/TMHMM/TMHMM2.0b.guide.php) or (ii) tmpred (from EMBnet, maintained by the ISREC Bionformatics group and the LICR Information Technology Office, Ludwig Institute for Cancer Research, Swiss Institute of Bioinformatics, http://w ⁇ w.ch.embnet.org/soflware/TMDPRED_form.html) for transmembrane region prediction; (iii) signalp imm or (iv) signalp_nn (both from Center for Biological Sequence Analysis, Technical University of Denmark DTU, http://www.cbs.dtu.dk services/S
  • signalp_hmm and “signalp_nn” refer to two modes of operation for the program SignalP: hmm refers to Hidden Markov Model, while nn refers to neural networks. Localization was also determined through manual inspection of known protein localization and/or gene structure, and the use of heuristics by the individual inventor.
  • T - > C means that the SNP results in a change at the position given in the table from T to C.
  • M - > Q means that the SNP has caused a change in the corresponding amino acid sequence, from methionine (M) to glutamine (Q). If, in place of a letter at the right hand side for the nucleotide sequence SNP, there is a space, it indicates that a frameshift has occurred. A frameshift may also be indicated with a hyphen (-). A stop codon is indicated with an asterisk at the right hand side (*).
  • a comment may be found in parentheses after the above description of the SNP itself.
  • This comment may include an FTId, which is an identifier to a SwissProt entry that was created with the indicated SNP.
  • An FTId is a unique and stable feature identifier, which allows construction of links directly from position- specific annotation in the feature table to specialized protein-related databases.
  • the header of the first column is "SNP position(s) on amino acid sequence", representing a position of a known mutation on amino acid sequence.
  • SNPs may optionally be used as diagnostic markers according to the present invention, alone or in combination with one or more other SNPs and/or any other diagnostic marker.
  • Preferred embodiments of the present invention comprise such SNPs, including but not limited to novel SNPs on the known (WT or wild type) protein sequences given below, as well as novel nucleic acid and/or amino acid sequences formed through such SNPs, and/or any SNP on a variant amino acid and/or nucleic acid sequence described herein.
  • a key to the p values with regard to the analysis of such overexpression is as follows: - library-based statistics: P- alue without including the level of expression in cell- lines (PI) - library based statistics: P- value including the level of expression in cell-lines (P2) - EST clone statistics: P- value without including the level of expression in cell- lines (SP1) - EST clone statistics: predicted overexpression ratio without including the level of expression in cell- lines (R3) - EST clone statistics: P- value including the level of expression in cell- lines (SP2) - EST clone statistics: predicted overexpression ratio including the level of expression in cell- lines (R4)
  • Library-based statistics refer to statistics over an entire library, while EST clone statistics refer to expression only for ESTs from a particular tissue or cancer.
  • microarrays As a microarray reference, in the specific segment paragraphs, the unabbreviated tissue name was used as the reference to the type of chip for which expression was measured. There are two types of microarray results: those from microarrays prepared according to a design by the present inventors, for which the microarray fabrication procedure is described in detail in Materials and Experimental Procedures section herein; and those results from microarrays using Affymetrix technology. As a microarray reference, in the specific segment paragraphs, the unabbreviated tissue name was used as the reference to the type of chip for which expression was measured.
  • the probe name begins with the name of the cluster (gene), followed by an identifying number.
  • Oligonucleotide microarray results taken from Affymetrix data were from chips available from Affymetrix Inc, Santa Clara, CA, USA (see for example data regarding the Human Genome U133 (HG-U133) Set at www.affymetrix.com/products/arrays/specific/hgul33.affx; GeneChip Human Genome U133A 2.0 Array at wvvw.affymetrix.com/products/arrays/specific/hgul33av2.affx; and Human Genome U133 Plus 2.0 Array at www.affymetrix.com/products/arrays/specific/hgul33plus.affx).
  • the probe names follow the Affymetrix naming convention.
  • the data is available from NCBI Gene Expression Omnibus (see www.ncbi.nlm.nih.gov/projects/geo/ and Edgar et al, Nucleic Acids Research, 2002, Vol. 30, No. 1 207-210).
  • the probes designed according to the present inventors are listed below.
  • TAA histograms The following list of abbreviations for tissues was used in the TAA histograms.
  • TAA Tumor Associated Antigen
  • TAA histograms represent the cancerous tissue expression pattern as predicted by the biomarkers selection engine, as described in detail in examples 1-5 below.
  • nucleic acid sequences of the present invention refer to portions of nucleic acid sequences that were shown to have one or more properties as described below. They are also the building blocks that were used to construct complete nucleic acid sequences as described in greater detail below.
  • oligonucleotides which are embodiments of the present invention, for example as amplicons, hybridization units and/or from which primers and/or complementary oligonucleotides may optionally be derived, and/or for any other use.
  • breast cancer refers to cancers of the breast or surrounding tissue, including but not limited to ductal carcinoma (in-situ or invasive), lobular carcinoma (in- situ or invasive), inflammatory breast cancer, mucinous carcinoma, tubular carcinoma, or Paget's disease of the nipple, as well as conditions that are indicative of a higher risk factor for later development of breast cancer, including but not limited to ductal hyperplasia without atypia and atypical hyperplasia, referred to herein collectively as "indicative conditions”.
  • the term "marker” in the context of the present invention refers to a nucleic acid fragment, a peptide, or a polypeptide, which is differentially present in a sample taken from subjects (patients) having breast cancer (or one of the above indicative conditions) as compared to a comparable sample taken from subjects who do not have breast cancer (or one of the above indicative conditions).
  • the phrase “differentially present” refers to differences in the quantity of a marker present in a sample taken from patients having breast cancer (or one of the above indicative conditions) as compared to a comparable sample taken from patients who do not have breast cancer (or one of the above indicative conditions).
  • a nucleic acid fragment may optionally be differentially present between the two samples if the amount of the nucleic acid fragment in one sample is significantly different from the amount of the nucleic acid fragment in the other sample, for example as measured by hybridization and or NAT-based assays.
  • a polypeptide is differentially present between the two samples if the amount of the polypeptide in one sample is significantly different from the amount of the polypeptide in the other sample. It should be noted that if the marker is detectable in one sample and not detectable in the other, then such a marker can be considered to be differentially present.
  • diagnosis means identifying the presence or nature of a pathologic condition. Diagnostic methods differ in their sensitivity and specificity.
  • the "sensitivity” of a diagnostic assay is the percentage of diseased individuals who test positive (percent of "true positives”). Diseased individuals not detected by the assay are “false negatives.” Subjects who are not diseased and who test negative in the assay are termed “true negatives.”
  • the "specificity” of a diagnostic assay is 1 minus the false positive rate, where the "false positive” rate is defined as the proportion of those without the disease who test positive. While a particular diagnostic method may not provide a definitive diagnosis of a condition, it suffices if the method provides a positive indication that aids in diagnosis.
  • Diagnosing refers to classifying a disease or a symptom, determining a severity of the disease, monitoring disease progression, forecasting an outcome of a disease and/or prospects of recovery.
  • the term “detecting” may also optionally encompass any of the above. Diagnosis of a disease according to the present invention can be effected by determining a level of a polynucleotide or a polypeptide of the present invention in a biological sample obtained from the subject, wherein the level determined can be correlated with predisposition to, or presence or absence of the disease.
  • a "biological sample obtained from the subject” may also optionally comprise a sample that has not been physically removed from the subject, as described in greater detail below.
  • the term "level” refers to expression levels of RNA and or protein or to DNA copy number of a marker of the present invention. Typically the level of the marker in a biological sample obtained from the subject is different (i.e., increased or decreased) from the level of the same variant in a similar sample obtained from a healthy individual (examples of biological samples are described herein). Numerous well known tissue or fluid collection methods can be utilized to collect the biological sample from the subject in order to determine the level of DNA, RNA and or polypeptide of the variant of interest in the subject. Examples include, but are not limited to, fine needle biopsy, needle biopsy, core needle biopsy and surgical biopsy (e.g., brain biopsy), and lavage.
  • test amount refers to an amount of a marker in a subject's sample that is consistent with a diagnosis of breast cancer (or one of the above indicative conditions).
  • a test amount can be either in absolute amount (e.g., microgram/ml) or a relative amount (e.g., relative intensity of signals).
  • a “control amount” of a marker can be any amount or a range of amounts to be compared against a test amount of a marker.
  • a control amount of a marker can be the amount of a marker in a patient with breast cancer (or one of the above indicative conditions) or a person without breast cancer (or one of the above indicative conditions).
  • a control amount can be either in absolute amount (e.g., microgram/ml) or a relative amount (e.g., relative intensity of signals).
  • Detect refers to identifying the presence, absence or amount of the object to be detected.
  • a “label” includes any moiety or item detectable by spectroscopic, photo chemical, biochemical, immunochemical, or chemical means.
  • useful labels include 32 P, 35 S, fluorescent dyes, electron-dense reagents, enzymes (e.g., as commonly used in an ELISA), biotin-streptavadin, dioxigenin, haptens and proteins for which antisera or monoclonal antibodies are available, or nucleic acid molecules with a sequence complementary to a target.
  • the label often generates a measurable signal, such as a radioactive, chromogenic, or fluorescent signal, that can be used to quantify the amount of bound label in a sample.
  • the label can be inco ⁇ orated in or attached to a primer or probe either covalently, or through ionic, van der Waals or hydrogen bonds, e.g., incorporation of radioactive nucleotides, or biotinylated nucleotides that are recognized by streptavadin.
  • the label may be directly or indirectly detectable. Indirect detection can involve the binding of a second label to the first label, directly or indirectly.
  • the label can be the ligand of a binding partner, such as biotin, which is a binding partner for streptavadin, or a nucleotide sequence, which is the binding partner for a complementary sequence, to which it can specifically hybridize.
  • the binding partner may itself be directly detectable, for example, an antibody may be itself labeled with a fluorescent molecule.
  • the binding partner also may be indirectly detectable, for example, a nucleic acid having a complementary nucleotide sequence can be a part of a branched DNA molecule that is in turn detectable through hybridization with other labeled nucleic acid molecules (see, e.g., P. D. Fahrlander and A. Klausner, Bio/Technology 6: 1165 (1988)). Quantitation of the signal is achieved by, e.g., scintillation counting, densitometry, or flow cytometry.
  • Exemplar ⁇ ' detectable labels include but are not limited to magnetic beads, fluorescent dyes, radiolabels, enzymes (e.g., horse radish peroxide, alkaline phosphatase and others commonly used in an ELISA), and calorimetric labels such as colloidal gold or colored glass or plastic beads.
  • the marker in the sample can be detected using an indirect assay, wherein, for example, a second, labeled antibody is used to detect bound marker-specific antibody, and/or in a competition or inhibition assay wherein, for example, a monoclonal antibody which binds to a distinct epitope of the marker are incubated simultaneously with the mixture.
  • Immunoassay is an assay that uses an antibody to specifically bind an antigen.
  • the immunoassay is characterized by the use of specific binding properties of a particular antibody to isolate, target, and/or quantify the antigen.
  • the specified antibodies bind to a particular protein at least two times greater than the background (non-specific signal) and do not substantially bind in a significant amount to other proteins present in the sample.
  • Specific binding to an antibody under such conditions may require an antibody that is selected for its specificity for a particular protein.
  • polyclonal antibodies raised to seminal basic protein from specific species such as rat, mouse, or human can be selected to obtain only those polyclonal antibodies that are specifically immunoreactive with seminal basic protein and not with other proteins, except for polymorphic variants and alleles of seminal basic protein. This selection may be achieved by subtracting out antibodies that cross-react with seminal basic protein molecules from other species.
  • immunoassay formats may be used to select antibodies specifically immunoreactive with a particular protein.
  • solid-phase ELISA immunoassays are routinely used to select antibodies specifically immunoreactive with a protein (see, e.g., Harlow & Lane, Antibodies, A Laboratory Manual (1988), for a description of immunoassay formats and conditions that can be used to determine specific immunoreactivity).
  • a specific or selective reaction will be at least twice background signal or noise and more typically more than 10 to 100 times background.
  • an isolated polynucleotide comprising a nucleic acid sequence in the table below and/or:
  • nucleic acid sequence comprising a sequence in the table below:
  • an isolated polypeptide comprising an amino acid sequence in the table below amino acid sequence comprising a sequence in the table below:
  • T10888_PEA_1. _P6 * According to preferred embodiments of the present invention, there is provided an isolated polynucleotide comprising a nucleic acid sequence in the table below and/or:
  • T39971 T5 a nucleic acid sequence comprising a sequence in the table below:
  • an isolated polypeptide comprising an amino acid sequence in the table below:
  • an isolated polynucleotide comprising a nucleic acid sequence in the table below and/or:
  • nucleic acid sequence comprising a sequence in the table below:
  • an isolated polypeptide comprising an amino acid sequence in the table below Protein Name Z21368_PEA_ X_P2 Z2136S_PEA_ .1-P5 Z21368_PEA_ .1JP15 Z21368 PEA 1 P16
  • an isolated polynucleotide comprising a nucleic acid sequence in the table below and/or:
  • T59832 a nucleic acid sequence comprising a sequence in the table below:
  • an isolated polypeptide comprising an amino acid sequence in the table below
  • JP18 According to preferred embodiments of the present invention, there is provided an isolated polynucleotide comprising a nucleic acid sequence in the table below and/or: Transcript Name Z41644_PEA 1 T5 a nucleic acid sequence comprising a sequence in the table below:
  • an isolated polypeptide comprising an amino acid sequence in the table below Protein Name Z41644_PEA 1 P10
  • an isolated polynucleotide comprising a nucleic acid sequence in the table below and/or: Transcript Name HUMGRP5E T4 HUMGRP5E_T5 a nucleic acid sequence comprising a sequence in the table below: Segment Name HUMGRP5E node 0 HUMGRP5E_node 2 HUMGRP5E node 8 HUMGRP5E node 3 HUMGRP5E rode 7
  • an isolated polypeptide comprising an amino acid sequence in the table below
  • an isolated polynucleotide comprising a nucleic acid sequence in the table below and/or: Transcript Name AA155578 PEA 1 T10 AA155578 PEA 1 T12
  • AA 155578 PEA 1 T8 a nucleic acid sequence comprising a sequence in the table below:
  • an isolated polypeptide comprising an amino acid sequence in the table below
  • an isolated polynucleotide comprising a nucleic acid sequence in the table below and or:
  • nucleic acid sequence comprising a sequence in the table below:
  • an isolated polypeptide comprising an amino acid sequence in the table below:
  • an isolated polynucleotide comprising a nucleic acid sequence in the table below and/or:
  • nucleic acid sequence comprising a sequence in the table below:
  • an isolated polypeptide comprising an amino acid sequence in the table below
  • T94936JPEA 1 P3 According to preferred embodiments of the present invention, there is provided an isolated polynucleotide comprising a nucleic acid sequence in the table below and/or:
  • nucleic acid sequence comprising a sequence in the table below:
  • an isolated polypeptide comprising an amino acid sequence in the table below
  • an isolated polynucleotide comprising a nucleic acid sequence in the table below and/or:
  • HSSTROL3 T12 a nucleic acid sequence comprising a sequence in the table below:
  • HSSTROL3 node 6 HSSTROL3 node 10 HSSTROL3 node 13 HSSTROL3 node 15 HSSTROL3 node 19 HSSTROL3 node 21 HSSTROL3_node_24 HSSTROL3 node 25 HSSTROL3_node 26 HSSTROL3 node 28 HSSTROL3 node 29 HSSTROL3 node 11 HSSTROL3_node 17 HSSTROL3 node 18 HSSTROL3 node 20 HSSTROL3 node 27
  • an isolated polypeptide comprising an amino acid sequence in the table below
  • an isolated polynucleotide comprising a nucleic acid sequence in the table below and/or: Transcript Name AY 180924 PEA 1 TI a nucleic acid sequence comprising a sequence in the table below:
  • an isolated polypeptide comprising an amino acid sequence in the table below
  • an isolated polynucleotide comprising a nucleic acid sequence in the table below and/or:
  • nucleic acid sequence comprising a sequence in the table below:
  • an isolated polypeptide comprising an amino acid sequence in the table below Protein Name R75793. -PEA_ .1_P2 R75793. -PEA. -1_P5 R75793. _PEA_ .1JP6
  • an isolated polynucleotide comprising a nucleic acid sequence in the table below and/or:
  • nucleic acid sequence comprising a sequence in the table below:
  • an isolated polypeptide comprising an amino acid sequence in the table below
  • an isolated polynucleotide comprising a nucleic acid sequence in the table below and/or: Transcript Name R20779_T7 a nucleic acid sequence comprising a sequence in the table below: Segment Name R20779_node 0 R20779 node 2 R20779 node 7 R20779 node 9 R20779 node 18 R20779 node 21 R20779_node 24
  • an isolated polypeptide comprising an amino acid sequence according to R20779_P2.
  • an isolated polynucleotide comprising a nucleic acid sequence in the table below and/or:
  • nucleic acid sequence comprising a sequence in the table below:
  • an isolated polypeptide comprising an amino acid sequence according to HSS100PCB_P3.
  • an isolated polynucleotide comprising a nucleic acid sequence in the table below and/or:
  • an isolated polynucleotide comprising a nucleic acid sequence in the table below and/or:
  • nucleic acid sequence comprising a sequence in the table below:
  • an isolated polynucleotide comprising a nucleic acid sequence in the table below and/or: Transcript Name HUMOSTRO PEA 1 PEA 1 T14 HUMOSTRO PEA 1 PEA 1 T16 HUMOSTRO PEA 1 PEA 1 T30 a nucleic acid sequence comprising a sequence in the table below: Segment Name HUMOSTROJPEA_l. _PEA. _l_node_0 HUMOSTROJPEA_l. _PEA. _l_node_10 HUMOSTRO_PEA_l.
  • _PEA_ _l_node_15 HUMOSTRO_PEA_l.
  • _PEA_ _l_node_17 HUMOSTRO_PEA_l.
  • _PEA_ .l_node_20 HUMOSTROJPEA.
  • _l_JPEA_l_node_21 HUMOSTRO_PEA_l.
  • an isolated polynucleotide comprising a polynucleotide having a sequence selected from the group consisting of: RI 1723_PEA_1_T15, RI 1723_PEA_1_T17, RI 1723_PEA_1_T19, RI 1723_PEA_1_T20 ; RI 1723_PEA_1_T5, or RI 1723_PEA_1_T6.
  • an isolated polynucleotide comprising a node having a sequence selected from the group consisting of : R11723_PEA_l_node_13, R11723_PEA_l_node_16, R11723_PEA_l_ ⁇ ode_19, RI 1723JPEA_l_node_2, RI 1723_PEA_l_node_22, RI 1723_PEA_l_ node_31, RI 1723JPEA_l_node_10, RI 1723_PEA_l_node_l 1, RI 1723 _PEA_l_node_15, RI 1723_PEA_l_node_18, RI 1723_PEA_l_node_20, RI 1723_PEA_l_node_21, RI 1723_PEA_l_node_23, RI 1723_PEA_l_node_23, RI 1723_
  • an isolated polypeptide comprising a polypeptide having a sequence selected from the group consisting of : RI 1723_PEA_1_P2, RI 1723_PEA_1_P6, RI 1723_PEA_1 JP7, R11723 PEA 1 P13, or R11723 PEA 1 P10.
  • an isolated polynucleotide comprising a nucleic acid sequence in the table below and/or:
  • T46984_PEA_ J_T54 a nucleic acid sequence comprising a sequence in the table below:
  • an isolated polynucleotide comprising a nucleic acid sequence in the table below and/or:
  • M78076_PEA_1. _T28 a nucleic acid sequence comprising a sequence in the table below:
  • an isolated polynucleotide comprising a nucleic acid sequence in the table below and/or:
  • HSMUC1AJ?EA_ JJT47 a nucleic acid sequence comprising a sequence in the table below:
  • HSMUCIA PEA 1 P63 According to prefe ⁇ ed embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for HSMUCl A_PEA_1_P63, comprising a first amino acid sequence being at least 90 % homologous to
  • MTPGTQSPFFLLLLLTNLT TGSGHASSTPGGEKETSATQRSSN co ⁇ esponding to amino acids 1 - 45 of MUCl JTUMA ⁇ , which also co ⁇ esponds to amino acids 1 - 45 of HSMUCl A JPE A_1JP63
  • a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90%) and most preferably at least 95% homologous to a polypeptide having the sequence EEEVSADQVSVGASGVLGSFKEARNAPSFLSWSFSMGPSK co ⁇ esponding to amino acids 46 - 85 of HSMUC1AJPEA_1 JP63, wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.
  • an isolated polypeptide encoding for a tail of HSMUCl AJPEA_1 JP63 comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence EEEVSADQVSVGASGVLGSFKEARNAPSFLSWSFSMGPSK in HSMUCl AJPEA_1_P63.
  • an isolated chimeric polypeptide encoding for T46984J D EA_1 JP2 comprising a first amino acid sequence being at least 90 % homologous to
  • FFQLVDV ⁇ TGAELTPHQ co ⁇ esponding to amino acids 1 - 433 of RIB2_HUMA ⁇ which also co ⁇ esponds to amino acids 1 - 433 of T469S4JPEA_1_P3, and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence ICHIWKLIFLP co ⁇ esponding to amino acids 434 - 444 of T46984JPEA_J_P3, wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.
  • an isolated chimeric polypeptide encoding for T46984J?EA_1 JP10 comprising a first amino acid sequence being at least 90 % homologous to
  • an isolated polypeptide encoding for a tail of T46984J?EA_1 JP10 comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence LMDQK in T46984JPEA_1_P10.
  • an isolated chimeric polypeptide encoding for T46984_PEA_1_P11 comprising a first amino acid sequence being at least 90 % homologous to
  • an isolated chimeric polypeptide encoding for T46984J?EA_1 JP12 comprising a first amino acid sequence being at least 90 % homologous to MAPPGSST LLALTIIASTWALTPTHYLTKHD ⁇ RLKASLDRPFTNLESAFYSINGLSSL GAQWDAKKACT ⁇ IRS ⁇ LDPS ⁇ VDSLFYAAQASQALSGCEISIS ⁇ ET DLLLAAVSEDSS VTQIYHAVAALSGFGLPLASQEALSALTARLSKEETVLATNQALQTASHLSQQADLRSI VEEEDLVA ⁇ DELGGVYLQFEEGLETT ⁇ VAAnT MDHVGTLPSIKEDQVIQLMNA
  • PLTQATVKLEHAKSVASRATVLQKTSFTPVGDVFELNFMN co ⁇ esponding to amino acids 1 - 338 of RIB2_HUMAN, which also co ⁇ esponds to amino acids 1 - 338 of T46984_PEA_1 JP12
  • a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence SQDLH co ⁇ esponding to amino acids 339 - 343 of T46984J?EA_1J?12, wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.
  • an isolated polypeptide encoding for a tail of T46984_PEA_1 JP12 comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence SQDLH in T469S4_PEA_1JP12.
  • an isolated chimeric polypeptide encoding for T46984JPEA_1JP21 comprising a first amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence M co ⁇ esponding to amino acids 1 - 1 of T46984J?EA_1 JP21, and a second amino acid sequence being at least 90 % homologous to
  • an isolated polypeptide encoding for a tail of T46984J?EA_1 JP27 comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence FGSGL ⁇ MSPTSLLLLARLYFTWDMLLCWDSCMSTGLSSTCSRP in T46984_PEA_1_P27.
  • an isolated chimeric polypeptide encoding for T46984JPEA_1 JP32 comprising a first amino acid sequence being at least 90 % homologous to MA PGSSTVFLLALTIIASTWALTPT TKJTD ⁇ TSP KASLDRPFTNLESAFYSIVGLSSL GAQVPDAKKACTYIRS ⁇ DPS ⁇ SLFYAAQASQALSGCEISISbffiTKDLLLAAVSEDSS VTQIYHAVAALSGFGLPLASQEALSALTARLSKEETVLATVQALQTASHLSQQADLRSI VEEffiDLVARLDELGGVYLQFEEGLETTALFVAATYKLMDHNGTEPSIKEDQVIQLMNA ITSKIs FESLSEAFSVASAAAVLSHNRYHWVNV EGSASDTHEQAIL PLTQATNKLEHAKSVASRATNLQKTSFTPVGD ELOTM ⁇ NKFSSGYYY
  • an isolated polypeptide encoding for a tail of T469S4JPEA_1 JP32 comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence GQVRWLTPVIPALWEAKAGGSPEVRSSILAWPT in T46984_PEA_1 JP32.
  • an isolated chimeric polypeptide encoding for T469S4JPEA_J_P34 comprising a first amino acid sequence being at least 90 % homologous to
  • PLTQATVKLEHAKSVASRATVLQKTSFTPVG co ⁇ esponding to amino acids 1 - 329 of RIB2_HUMAN, which also co ⁇ esponds to amino acids 1 - 329 of T46984_PEA_1_P34.
  • an isolated chimeric polypeptide encoding for T46984JPEA_1 JP35 comprising a first amino acid sequence being at least 90 % homologous to MAPPGSSTVFLLALTIIASTWALTPTmXTi aD ⁇ ERLKASLDRPFTNLESAFYSINGLSSL GAQWDA KACTYIRS ⁇ LDPS ⁇ VDSLFYAAQASQALSGCEISIS ⁇ ETKDLLLAAVSEDSS VTQIYHAVAALSGFGLPLASQEALSALTARLSKEETVLATVQALQTASHLSQQADLRSI VEEIEDLVARLDELGGV TQFEEGLETTALFVAATNKLMDHVGTEPSIKEDQVIQLMNA ITSKKNFESLSEAFSVASAAAVLSHNRYHVPVVVVPEGSASDTHEQAI co ⁇ esponding to amino acids 1 - 287 of PJB2 JHUMAN, which also co ⁇ esponds
  • an isolated polypeptide encoding for a tail of T46984_PEA_1_P35 comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence GCWPSRQSREQHISSRRKMEILKTECQEK ⁇ SRT SMRRKMEKKNFI in T46984_PEA_1_P35.
  • an isolated chimeric polypeptide encoding for T46984J?EA_1_P38 comprising a first amino acid sequence being at least 90 % homologous to MAPPGSSTWLLALTIIASTWALTPTHYI.TK ⁇ DVERLKASLDRPFTNLESAFYSIVGLSSL GAQWDAKKACTYIRSNLDPSN ⁇ SLFYAAQASQALSGCEISISNETKDLLLAAVSEDSS VTQIYHAVAALSGFGLPLASQEAL co ⁇ esponding to amino acids 1 - 145 of PJB2_HUMAN, which also co ⁇ esponds to amino acids 1 - 145 of T46984_PEA_1_P38, and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence MDPDWCQCLQL
  • an isolated polypeptide encoding for a tail of T46984J?EA_1 JP3S comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90%) and most preferably at least about 95% homologous to the sequence MDPDWCQCLQLHFCS in T469S4_PEA_1 JP3S.
  • an isolated chimeric polypeptide encoding for T46984J?EA_1 JP39 comprising a first amino acid sequence being at least 90 % homologous to
  • VTQ ⁇ YHAVAALSGFGLPLASQEALSALTARLSKEETVLA co ⁇ esponding to amino acids 1 - 160 of RIB2_HUMAN, which also co ⁇ esponds to amino acids 1 - 160 of T46984JPEA_1JP39.
  • an isolated chimeric polypeptide encoding for T46984J?EA_1 JP45 comprising a first amino acid sequence being at least 90 % homologous to MAPPGSST LLALTIIASTWALTPTHYLTKHDVERLKASLDRPFTNLESAFYSIVGLSSL
  • T46984JPEA_1 JP45 and a second amino acid sequence being at least 70%, optionally at least
  • an isolated polypeptide encoding for a tail of T46984JPEA_J_P45 comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence
  • NSPGSADSIPPVPAG in T46984_PEA_1_P45 there is provided an isolated chimeric polypeptide encoding for T469S4JPEA_J JP46, comprising a first amino acid sequence being at least 90 % homologous to
  • an isolated polypeptide encoding for a tail of T46984J?EA_1 JP46 comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence NSPGSADSIPPVPAG in T46984_PEA_1_P46.
  • an isolated chimeric polypeptide encoding for TI 1628_PEA_1_P2 comprising a first amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence MGLSDGEWQLVLNVWGKVEADIPGHGQEVLIP FKGHPETLEKJDK i LKSEDE co ⁇ esponding to amino acids 1 - 55 of TI 1628 JPE A_l JP2, and a second amino acid sequence being at least 90 % homologous to MKASEDLKK ⁇ GATVLTALGGILKI ⁇ &GHHEAEIKPLAQSHATKHKIPVKYLEFISECIIQV LQSKXTPGDFGADAQGAMNKALELFRKDMASNYKELGFQG co ⁇ esponding to amino acids 1 - 99 of Q8WVH6, which also co ⁇
  • an isolated polypeptide encoding for a head of TI 1628JPEA_1_P2 comprising a polypeptide being at least 10%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence MGLSDGEWQL ⁇ T.
  • an isolated chimeric polypeptide encoding for TI 1628JPEA_J JP5 comprising a first amino acid sequence being at least 90 % homologous to IVlKASEDLKKHGATVLTALGGELKKKGH LQSKHPGDFGAJ AQGAMNKALELFRKDMASNYKELGFQG co ⁇ esponding to amino acids 56 - 154 of MYG_HUMAN_V1, which also co ⁇ esponds to amino acids 1 - 99 of T1162S_PEA_1_P5.
  • an isolated chimeric polypeptide encoding for TI 1628_PEA_1 JP7 comprising a first amino acid sequence being at least 90 % homologous to
  • SKHPGDFGADAQGAMNK co ⁇ esponding to amino acids 1 - 134 of M r G_HUMAN_Vl, which also co ⁇ esponds to amino acids 1 - 134 of TI 1628JPEA_1 JP7, and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence G co ⁇ esponding to amino acids 135 - 135 of TI 1628 JPE A_1JP7, wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.
  • an isolated chimeric polypeptide encoding for TI 1628JPEA_1_P10 comprising a first amino acid sequence being at least 70%, optionally at least S0%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence MGLSDGEWQL ⁇ NVWGKVEADIPGHGQEVLIPJ.FKGFfPETLEKJDKFKHLKSEDE co ⁇ esponding to amino acids 1 - 55 of TI 1628JPEA_J JP10, and a second amino acid sequence being at least 90 % homologous to MKASEDLKKHGATVLTA GGILKKKGHffi
  • LQSKHPGDFGADAQGAMNKALELFRKDMASNYKELGFQG co ⁇ esponding to amino acids 1 - 99 of Q8WVH6, which also co ⁇ esponds to amino acids 56 - 154 of TI 1628_PEA_1_P10, wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.
  • an isolated polypeptide encoding for a head of TI 1628_PEA_1_P10 comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence MGLSDGEWQLVLNNWGKNEAI IPGHGQEVLIRLFKGHPETXEK.FDKFK ⁇ LKSEDE of T1 ⁇ 628JPEA_J_P10.
  • an isolated polypeptide encoding for a tail of M78076JPEA_1 JP4 comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence ECLTVNPSLQFPLNP in M78076_PEA_1_P4.
  • an isolated chimeric polypeptide encoding for M78076JPEA_1 JP12 comprising a first amino acid sequence being at least 90 % homologous to
  • an isolated polypeptide encoding for a tail of M78076jPEA_l _P12 comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence ECVCSKGFPFPLIGDSEG in M78076JPEA_1JP12.
  • an isolated chimeric polypeptide encoding for M78076JPEA_1 JP14 comprising a first amino acid sequence being at least 90 % homologous to MGPASPAARGLSRRPGQPPLPLLLPLLLLLLRAQPAIGSLAGGSPGAAEAPGSAQVAGL CGRLTLHRDLRTGRWEPDPQRSRRCLRDPQRVLE YCRQM YPELQIARVEQATQAIPME RWCGGSRSGSCAHPHHQWPFRCLPGEFVSEALLVPEGCRFLHQERMDQCESSTRRHQ EAQEACSSQGLILHGSGMLLPCGSDRFRGVEYVCCPPPGTPDPSGTAVGDPSTRSWPPG SRVEGAEDEEEEESFPQP ⁇ T)DYF ⁇ /EPPQAEEEEET PPSSHTLA GKVTPTPRPTDGV DIYFGMPGEISEHEGFLRAKMDLEERR ⁇ RQI ⁇ EVMREWA ⁇ 1A
  • an isolated polypeptide encoding for a tail of M78076JPEA_1 JP14 comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence VRGGTAGYLGEETRGQRPGCDSQSHTGPSKKPSAPSPLPAGTSWDRGVP in M78076JPEA_1J 3 14.
  • an isolated chimeric polypeptide encoding for M78076JPEA_1 JP21 comprising a first amino acid sequence being at least 90 % homologous to MGPASPAARGLSRRPGQPPLPLLLPLLLLLLRAQPAIGSL AGGSPG A AE APGS AQ V AGL CGRLTLHRDLRTGRWEPDPQRSRRCLRDPQRVLEYCRQMYPELQIARVEQATQAIPME RWCGGSRSGSCAHPHHQWPFRCLPGEFVSEALLVPEGCRFLHQERMDQCESSTRRHQ EAQEACSSQGLILHGSGMLLPCGSDRFRGVEYVCCPPPGTPDPSGTAVGDPSTRSWPPG SRVEGAEDEEEEESFPQPVDDYFVEPPQAEEEEETVPPPSSHTLAWGKVTPTPRPTDGV DIYFGMPGEISEHEGFLP ⁇ ⁇ lDLEERRMRQINEVMREWAMAX)N
  • NPTYRFLEERP co ⁇ esponding to amino acids 406 - 650 of APP1_HUMAN, which also co ⁇ esponds to amino acids 353 - 597 of M78076JPEA_1JP21, wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.
  • an isolated chimeric polypeptide encoding for an edge portion of M78076JPEA_J JP21 comprising a polypeptide having a length "n", wherein n is at least about 10 amino acids in length, optionally at least about 20 amino acids in length, preferably at least about 30 amino acids in length, more preferably at least about 40 amino acids in length and most preferably at least about 50 amino acids in length, wherein at least two amino acids comprise EA, having a structure as follows: a sequence starting from any of amino acid numbers 352-x to 352; un ⁇ ending at any of amino acid numbers 353+ ((n-2) - x), in which x varies from 0 to n-2.
  • an isolated chimeric polypeptide encoding for M78076JPEA_1_P24 comprising a first amino acid sequence being at least 90 % homologous to
  • an isolated polypeptide encoding for a tail of M78076_PEA_1_P24 comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence RECLLPWLPLQISEGRS in M78076JPEA_1_P24.
  • ALRRYLRAEQKEQRHTLRHYQHVAAVDPEKAQQMRFQV co ⁇ esponding to amino acids 1 - 449 of APP1 JHUMAN, which also co ⁇ esponds to amino acids 1 - 449 of M78076J?EA_1 JP2, and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence
  • an isolated chimeric polypeptide encoding for M78076JPEA_1_P25 comprising a first amino acid sequence being at least 90 % homologous to
  • ALRRYLRAEQKEQRHTLRHYQHVAAVDPEKAQQMRFQ co ⁇ esponding to amino acids 1 - 448 of APP1_HUMAN, which also co ⁇ esponds to amino acids 1 - 448 of M78076JPEA_1_P25, and a second amino acid sequence being at least 70%, optionally at least 80%), preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence
  • PQNPNSQPP ⁇ . ⁇ GSLEVIISHPFVPJlLE ⁇ LISPFQFQNSIPKNSQlVPAASPRGTSSP co ⁇ esponding to amino acids 449 - 505 of M78076JPEA_1_P25, wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.
  • an isolated polypeptide encoding for a tail of M78076J?EA_1 JP25 comprising a polypeptide being at least 70%, optionally at least about 80%), preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence PQNPNSQPPvAAGSLEV ⁇ SHPF ⁇ RRLEILISPFQFQNSIPKNSQiVPAASPRGTSSP in M78076_PEA_1JP25.
  • an isolated chimeric polypeptide encoding for M85491JPEA_J_P13 comprising a first amino acid sequence being at least 90 % homologous to MALRRLGAALLLLPLLAAVEETLMDSTTATAELGWMVHPPSGWEEVSGYDENMNTIR TYQVC ⁇ FVFESSQNNWLRTK ⁇ IRRRGAHRIHNE ⁇ I FSNRDCSSIPSWGSCKETF LYYY EADFDSATKTFPNWMENPWVKVDTIAADESFSQVDLGGRVMKTNTEVRSFGPVSRSGF YLAFQDYGGCMSLIAVRVFYRKCPRIIQNGAIFQETLSGAESTSLVAARGSCIANAEEVD VPIKLYCNGDGEWLVPIGRCMCKAGFEANENGTVCRGCPSGTFKANQGDEACTHCPLN SRTTSEGATNCVCRNGYYRADLDPLDMPCTTIPSAPQAVISSVNETSLMLEWTPPR
  • an isolated polypeptide encoding for a tail of M85491 _PEA_1_P13 comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence VPIGWVLSPSPTSLRAPLPG in MS5491_PEA_1JP13.
  • an isolated chimeric polypeptide encoding for M85491 JPEA_1 JP14 comprising a first amino acid sequence being at least 90 % homologous to
  • ERQDLTMLSRLVLNSWPQMILPPQPPKVLEL co ⁇ esponding to amino acids 271 - 301 of M85491 JPEA_1 JP14, wherein said first and second amino acid sequences are contiguous and in a sequential order.
  • an isolated polypeptide encoding for a tail of M85491 JPEA_1 JP14 comprising a polypeptide being at least 70%, optionally at least about 80%>, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence ERQDLTMLSRLVLNSWPQMJLPPQPPKVLEL in MS5491_PEA_1_P14.
  • an isolated chimeric polypeptide encoding for HSSTROL3 JP4 comprising a first amino acid sequence being at least 90 % homologous to
  • WQLVQEQVRQTMAEAJLKNWSDVTPLTFTEVHEGRADIMIDFARYW co ⁇ esponding to amino acids 1 - 163 of MM11 JHUMAN, which also co ⁇ esponds to amino acids 1 - 163 of
  • HSSTROL3JP4 a bridging amino acid H co ⁇ esponding to amino acid 164 of HSSTROL3_P4, a second amino acid sequence being at least 90 % homologous to
  • an isolated polypeptide encoding for a tail of HSSTROL3JP4 comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence ALGVRQLVGGGHSSRFSHLVVAGLPHACHRKSGSSSQVLCPEPSALLSVAG in HSSTROL3JP4.
  • an isolated chimeric polypeptide encoding for HSSTROL3 JP5 comprising a first amino acid sequence being at least 90 % homologous to
  • an isolated polypeptide encoding for a tail of HSSTROL3JP5 comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90%» and most preferably at least about 95% homologous to the sequence ELGFPSSTGRDESLEHCRCQGLHK in HSSTROL3_P5.
  • an isolated chimeric polypeptide encoding for H8STROL3JP7 comprising a first amino acid sequence being at least 90 % homologous to ⁇ LAPAAWLRSAAARALLPPMLLLLLQPPPLLAPvALPPDVHHLHAERRGPQPWHAALPSS PAPAPATQEAPRPASSLPPPRCGVPDPSDGLSARMlQKRFVLSGGRWEKTDLTYRILRFP WQLVQEQVRQTMAEALKVWSDVTPLTFTEVHEGRADIMIDFARYW co ⁇ esponding to amino acids 1 - 163 of MM11 JHUMAN, which also co ⁇ esponds to amino acids 1 - 163 of HSSTROL3JP7, a bridging amino acid H co ⁇ esponding to amino acid 164 of HSSTROL3JP7, a second amino acid sequence being at least 90 % homologous to GDDLPFDGPGGILAILAFFPKTHR
  • an isolated polypeptide encoding for a tail of HSSTROL3 JP7 comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence TTGVSTPAPGV in HSSTROL3JP7.
  • an isolated chimeric polypeptide encoding for HSSTROL3JP8 comprising a first amino acid sequence being at least 90 % homologous to
  • HSSTROL3JP8 a bridging amino acid H co ⁇ esponding to amino acid 164 of HSSTROL3JPS, a second amino acid sequence being at least 90 % homologous to
  • an isolated polypeptide encoding for a tail of HSSTROL3JPS comprising a polypeptide being at least 70%), optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence VRPCLPVPLLLCWPL in HSSTROL3_P8.
  • an isolated chimeric polypeptide encoding for HSSTROL3 JP9 comprising a first amino acid sequence being at least 90 % homologous to LAPAAWLRSAAARA LPPMLLLLLQPPPLLAPxALPPDVHHLHAERRGPQPWHAALPSS PAPAPATQEAPRPASSLRPPRCGVPDPSDGLSARNRQK co ⁇ esponding to amino acids 1 - 96 of MMl 1 JHUMAN, which also co ⁇ esponds to amino acids 1 - 96 of HSSTROL3JP9, a second amino acid sequence being at least 90 % homologous to PJLRFPWQLVQEQVRQTMAEAX.KVWSDVTPLTFTEVHEGPvADOvlLDFARYW co ⁇ esponding to amino acids 113 - 163 of MMl 1 JHUMAN, which also co ⁇ esponds to amino acids 97 - 147 of HSSTROL3JP
  • an isolated chimeric polypeptide encoding for an edge portion of HSSTROL3 JP9 comprising a polypeptide having a length "n", wherein n is at least about 10 amino acids in length, optionally at least about 20 amino acids in length, preferably at least about 30 amino acids in length, more preferably at least about 40 amino acids in length and most preferably at least about 50 amino acids in length, wherein at least two amino acids comprise KR, having a structure as follows: a sequence starting from any of amino acid numbers 96-x to 96; and ending at any of amino acid numbers 97+ ((n-2) - x), in which x varies from 0 to n-2.
  • an isolated polypeptide encoding for a tail of HSSTROL3 JP9 comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence TTGVSTPAPGV in HSSTROL3 JP9.
  • an isolated chimeric polypeptide encoding for AYl 80924JPEA_J_P3 comprising a first amino acid sequence being at least 90 % homologous to
  • MLNNSGLFVLLCGLLVSSSAQEVLAGVSSQLLN co ⁇ esponding to amino acids 1 - 33 of LATH JHUMAN, which also co ⁇ esponds to amino acids 1 - 33 of AYl 80924 _PEA_1 JP3, and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence GETVLLWVMQNPEPMPVKFSLAKYLGHNEHY co ⁇ esponding to amino acids 34 - 64 of AY 180924 JPEA_1_P3, wherein said first and second amino acid sequences are contiguous and in a sequential order.
  • an isolated chimeric polypeptide encoding for R75793 _PEA_1 JP2 comprising a first amino acid sequence being at least 90 % homologous to
  • an isolated chimeric polypeptide encoding for HUMCA1XIAJP14 comprising a first amino acid sequence being at least 90 % homologous to
  • an isolated polypeptide encoding for a tail of HUMCA1XIAJP14 comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence VSMMIINSQTIMVNNYSSSFrTLML in HUMCA1XIA_P14.
  • an isolated chimeric polypeptide encoding for HUMCA1XIAJP15 comprising a first amino acid sequence being at least 90 % homologous to
  • PIGPPGEK co ⁇ esponding to amino acids 1 - 714 of CA1BJHUMAN which also co ⁇ esponds to amino acids 1 - 714 of HUMCA1XIAJP15
  • a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%), more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence MCCNLSFGILIPLQK co ⁇ esponding to amino acids 715 - 729 of HUMCA1XIAJP15, wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.
  • an isolated polypeptide encoding for a tail of HUMCA1XIAJP15 comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence MCCNLSFGILIPLQK in HUMCAIXIA JP15.
  • an isolated chimeric polypeptide encoding for HUMCA1XIAJP16 comprising a first amino acid sequence being at least 90 % homologous to
  • an isolated chimeric polypeptide encoding for an edge portion of HUMCA1XIAJP16 comprising a polypeptide having a length "n", wherein n is at least about 10 amino acids in length, optionally at least about 20 amino acids in length, preferably at least about 30 amino acids in length, more preferably at least about 40 amino acids in length and most preferably at least about 50 amino acids in length, wherein at least two amino acids comprise AG, having a structure as follows: a sequence starting from any of amino acid numbers 648-x to 648; and ending at any of amino acid numbers 649+ ((n-2) - x), in which x varies from 0 to n-2.
  • an isolated polypeptide encoding for a tail of HUMCA1XIAJP16 comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85?/ 0 , more preferably at least about 90% and most preferably at least about 95% homologous to the sequence VSFSFSLFYKXVKFACDKRFNGRHDERKVVKLSLPLYLrYE in HUMCA1XLAJP16.
  • an isolated chimeric polypeptide encoding for HUMCA1XIAJ 17, comprising a first amino acid sequence being at least 90 % homologous to IEPWSSRWKTKPWLWDFTVTTLALTFLFQAJIEVRGAAPVDVLKALDFH ⁇ SPEGISKTT GFCT ⁇ T K ⁇ SKGSDTAYRVSKQAQLS.
  • an isolated polypeptide encoding for a tail of HUMCA1XIAJP17 comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence VRSTRPEK ⁇ FVFQ in HUMCA1XLA_P17.
  • an isolated chimeric polypeptide encoding for R20779_P2 comprising a first amino acid sequence being at least 90 % homologous to MCAERLGQFMTLALVLATFDPARGTDATNPPEGPQDRSSQQKGRLSLQNTAEIQHCLV NAGDVGCG ECFENNSCEIRGLHGICMTTH.HNAGKFDAQGKSFIKDALKCKAHALRH RFGCISRKCPA EMVSQLQRECYLKIHDLCAAAQENTRVIVEMIHFKDLLLHE co ⁇ esponding to amino acids 1 - 169 of STC2 JHUMAN, which also co ⁇ esponds to amino acids 1 - 169 of R20779JP2, and a second amino acid sequence being at least 70%, optionally at least 80%), preferably at least 85%, more preferably at least 90%> and most preferably at least 95%> homologous to a polypeptide having the sequence CYKIEITTV
  • an isolated polypeptide encoding for a tail of R20779JP2 comprising a polypeptide being at least 70%), optionally at least about 80%), preferably at least about 85%, more preferably at least about 90%) and most preferably at least about 95% homologous to the sequence CYKIEITMPKRRKVKLRD in R20779_P2.
  • HSCOC4JPEA_l JP5 and a second amino acid sequence being at least 70%, optionally at least 80%), preferably at least 85%, more preferably at leant 90% and most preferably at least 95% homologous to a polypeptide having the sequence D TLSGPQVTLLPFPCTPAPCSLCS co ⁇ esponding to amino acids 819 - 843 of HSCOC _PEA_l J?5, wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.
  • an isolated polypeptide encoding for a tail of HSCOC4JPEA_l_P5 comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90%> and most preferably at least about 95% homologous to the sequence DVTLSGPQNrLLPFPCTPAPCSLCS in HSCOC4_PEA_l JP5.
  • an isolated chimeric polypeptide encoding for HSCOC4_PEA_J JP6 comprising a first amino acid sequence being at least 90 % homologous to
  • HSCOC4JPEA_l JP12 an isolated chimeric polypeptide encoding for HSCOC4JPEA_l JP12, comprising a first amino acid sequence being at least 90 % homologous to MRLLWGL ⁇ WASSFFTLSLQKPRLLLFSPS WHLG VPLSVGVQLQDVPRGQWKGSVFLR
  • an isolated polypeptide encoding for a tail of HSCOC4JPEA Vietnamese JP 12 comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence RAREGVGPGTGGGEGVE in HSCOC4JPEA_l_P12.
  • an isolated chimeric polypeptide encoding for HSC0C4JPEA_1JP15 comprising a first amino acid sequence being at least 90 % homologous to
  • an isolated polypeptide encoding for a tail of HSCOC4JPEA_l JP15 comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence V ⁇ HSLV ⁇ HSLAWVARTPGPRGQARSRPQPPTRG ⁇ PAALLPGVFGGRLTSWLRDLEL in HSCOC4_PEA_l_P15.
  • an isolated chimeric polypeptide encoding for HSC0C4JPEA_1JP16 comprising a first amino acid sequence being at least 90 % homologous to MRLLWGLIWASSFFTLSLQKPRLLLFSPSVVHLGVPLSVGVQLQDVPRGQWKGSVFLR ⁇ PSR ⁇ NPCSPKVDFTLSSERDFALLSLQVPLKDAKSCGLHQLLRGPEVQLVAHSPWLK DSLSRTTNIQGINLLFSSRRGHLFLQTDQPIYNPGQRVRYR AI.DQKMPVPSTDTITVMV ENSHGLRVRKI ⁇ TVRPSSIFQDDFVIPDISEPGTWKJSARFSDGLESNSSTQF PNFEVKITPGKPYILT GHLDEMQLDIQARYIYGKPVQGVAYVRFGLLDEDGKKTFFR GLESQTKLVNGQSFFLSLSKAEFQDALEKL ⁇ U G
  • YTMEA ffiDYEDYEYDELPAJ ⁇ DPDA LQPVTPLQLFEGRRMlRR EAPK co ⁇ esponding to amino acids 1 - 1457 of C04JHUMANJ 1, which also co ⁇ esponds to amino acids 1 - 1457 of HSCOC4J?EA_l JP16, and a second amino acid sequence being at least 70%, optionally at least 80%), preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence
  • an isolated polypeptide encoding for a tail of HSCOC4_PEA_J J?16 comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence AERQGGANWHGHRGRHPPEWPRPAC in HSC0C4JPEA_1JP16.
  • an isolated chimeric polypeptide encoding for HSCOC4 JPEA_1 JP20 comprising a first amino acid sequence being at least 90 % homologous to
  • QGSFQGGFRSTQ co ⁇ esponding to amino acids 1 - 1303 of C04_HUMAN_V1, which also co ⁇ esponds to amino acids 1 - 1303 of HSCOC4JPEA_l JP20
  • a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence VGAVPGLWRGW ⁇ NLRPRACLSPGSTSLGHGDCPGCPVCLLDCLPHH co ⁇ esponding to amino acids 1304 - 1349 of HSCOC4JPEA_l JP20, wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.
  • an isolated polypeptide encoding for a tail of HSCOC4JPEA_l JP20 comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90%) and most preferably at least about 95% homologous to the sequence VGAVPGLWRGWWLRPRACLSPGSTSLGHGDCPGCPVCLLDCLPHH in HSCOC4JPEA_1JP20.
  • an isolated chimeric polypeptide encoding for HSCOC4JPEA_J JP9 comprising a first amino acid sequence being at least 90 % homologous to
  • YFDSV co ⁇ esponding to amino acids 1 - 1529 of C04 JHUMAN V 1 , which also co ⁇ esponds to amino acids 1 - 1529 of HSC0C4J?EA_1JP9
  • a second amino acid sequence being at least 10%, optionally at least 80%, preferably at least 85%, more preferably at least 90%> and most preferably at least 95% homologous to a polypeptide having the sequence SGER co ⁇ esponding to amino acids 1530 - 1533 of HSCOC4_PEA_l_P9, wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.
  • an isolated polypeptide encoding for a tail of HSCOC4_PEA_l_P9 comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about S5%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence SGER in HSCOC4_PEA_l_P9.
  • an isolated chimeric polypeptide encoding for HSCOC4JPEA_l JP22 comprising a first amino acid sequence being at least 90 % homologous to MRLLWGLIWASSFFTLSLQKPRLLLFSPSVVHLGVPLSVGVQLQDVPRGQWKGSVFLR NPSRNN ⁇ PCSPKVDFTLSSERDFALLSLQVPLKDAKSCGLHQLLRGPEVQLVAHSPWLK DSLSRTTNIQGINLLFSSRRGHLFLQTDQPIYNPGQRVRYRVFALDQKMRPSTDTITVMV ENSHGLRVRKKEVYMPSSIFQDDFVIPDISEPGTWKISAJRFSDGLESNSSTQFEVKKYVL PNFEVKITPGKPYILTVPGHLDEMQLDIQARYIYGKPVQGVAY FGLLDEDGKKTFFR GLESQTKLVNGQSHISLSKAEFQDALEKL
  • RLFETKITQVLHF co ⁇ esponding to amino acids 1 - 1653 of C04JHUMA ⁇ _V1, which also co ⁇ esponds to amino acids 1 - 1653 of HSCOC4J?EA_l JP22
  • a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence SMKQTGEAGRAGGRQGG co ⁇ esponding to amino acids 1654 - 1670 of HSCOC4J?EA_l JP22, wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.
  • an isolated polypeptide encoding for a tail of HSCOC4J?EA_l_P22 comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence SMKQTGEAGRAGGRQGG in HSCOC4_PEA_l JP22.
  • an isolated chimeric polypeptide encoding for HSCOC4JPEA_l JP23 comprising a first amino acid sequence being at least 90 % homologous to
  • an isolated polypeptide encoding for a tail of HSCOC4J?EA_l JP23 comprising a polypeptide being at least 70%, optionally at least about S0%>, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence QSSHRGPGLTLPRGPAVLVSLGVACSSYRSCTQPVCSDTNFLPSQPQSNSPFPLLLTPS in HSC0C4JPEA_1JP23.
  • an isolated chimeric polypeptide encoding for HSCOC4_PEA_l_P24 comprising a first amino acid sequence being at least 90 % homologous to
  • an isolated polypeptide encoding for a tail of HSCOC4JPEA_l JP24 comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence SADVLCFTGHQVRADSWPPCVLLKSASVLRGSALASVAPWSGVCRTRMATG in HSCOC4_PEA_JJP24.
  • an isolated chimeric polypeptide encoding for H8COC4JPEA_l JP25 comprising a first amino acid sequence being at least 90 % homologous to MRLLWGLIWASSFFTLSLQKPRLLLFSPSWHLGVPLSVGVQLQDVPRGQWKGSVFLR NPSRNNVPCSPKVDFTLSSERDFALLSLQVPLKDAKSCGLHQLLRGPEVQLVAHSPWLK DSLSRTTMQG ⁇ NLLFSSRRGHLFLQT ⁇ QPIYNPGQRVRYRWALDQKMRPSTDTITVMV ENSHGLRVRI K ⁇ VYMPSSIFQDDFVIPDISEPGT KISARFSDGLESNSSTQFEVKKYNL
  • SAEVCQCAEG co ⁇ esponding to amino acids 1 - 1593 of C04JHUMAN _V1, which also co ⁇ esponds to amino acids 1 - 1593 of HSCOC4J?EA_l JP25, and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence ETEGLGRGSGGGMAGAPPTLSDGFPNFREVPSPASRPGAGSAGRGWLQDEVCLLLPPC GVRLPG co ⁇ esponding to amino acids 1594 - 1657 of HSCOC4_PEA_l_P25, wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.
  • an isolated polypeptide encoding for a tail of HSCOC4jPEA_l JP25 comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%>, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence ETEGLGRGSGGGMAGAPPTLSDGFPNFREVPSPASRPGAGSAGRGWLQDEVCLLLPPC GVRLPG in HSCOC4JPEA_l_P25.
  • an isolated chimeric polypeptide encoding for HSCOC4_PEA_l JP26 comprising a first amino acid sequence being at least 90 % homologous to
  • SAEVCQCAEG co ⁇ esponding to amino acids 1 - 1593 of C04 JHUMAN _V1, which also co ⁇ esponds to amino acids 1 - 1593 of HSCOC4_PEA_l_P26, and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence ETEGLGRGSGGGMAGAPPTLSDGFPNFREVPSPASRPGAGSAGRGWLQDEVCLLLPPC GVRSVFPPRPWPDPPSGTGCFGLSGCSLLLLQVMHAACLL co ⁇ esponding to amino acids 1594 - 1691 of HSCOC4J?EA_l JP26, wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.
  • an isolated polypeptide encoding for a tail of HSCOC4J?EA_l_P26 comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%), more preferably at least about 90% and most preferably at least about 95% homologous to the sequence ETEGL GRGSGGGMAGAPPTLSDGFPNFRE VPSPASRPGAGSAGRGWLQDEVCLLLPPC GVRSVFPPRPWPDPPSGTGCFGLSGCSLLLLQVMHAACLL in HSCOC4_PEA_l JP26.
  • an isolated chimeric polypeptide encoding for HSCOC4JPEA_l JP30 comprising a first amino acid sequence being at least 90 % homologous to MRLLWGLIWASSFFTLSLQKPRLLLFSPSWHLGVPLSVGVQLQDVPRGQWKGSVFLR NPSRNNVPCSPKVDFTLSSERDFALLSLQVPLKDAKSCGLHQLLRGPEVQLVAHSPWLK DSLSRTTMQG ⁇ NLLFSSRRGHLFLQTDQPIYNPGQRVRYRVFALDQKMRPSTDTITVMV ENSHGLRVRKKEVY ⁇ 4PSSIPQDDFVIPDISEPGTN SAPJ ⁇ SDGLESNSSTQFEVKK ⁇ NL PNFEVKITPGKPYILTVPGFFL.DEMQLDIQARYLYGKPVQGVAYVRFGLLDEDGKKTFFR GLESQTKLVNGQSMSLSKAEFQDALEKL
  • an isolated polypeptide encoding for a tail of HSC0C4JPEA_1 JP30 comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence RNPVRLLQPRAQMFCVLRGTK in HSCOC4JPEA_1_P30.
  • an isolated chimeric polypeptide encoding for HSCOC4_PEA_l_P38 comprising a first amino acid sequence being at least 90 % homologous to MRLLWGLIWASSFFTLSLQKPRLLLFSPSWHLGVPL8VGVQLQDVPRGQWKGSVFLR NPSRNNNPCSPKVDFTLSSERDFALLSLQVPLKDAKSCGLHQLLRGPEVQLVAHSPWLK DSLSRTTMQGINLLFSSRRGHLFLQTDQPIYNPGQRVRYRVFALDQKMRPSTDTITNMN E ⁇ SHGLRVPJ ⁇ H EW / MPSSIFQDDFVIPDISEPGT ⁇ T SAILFSDGLES ⁇ SSTQFE ⁇ KYVL PNFEV TPGKP TLTNPGHLDEMQLDIQAI ⁇ YIYGKPVQGVAYVRFGLLDEDGKKTFFR GLESQTKLV ⁇ GQSFFLSLSKAEF
  • an isolated polypeptide encoding for a tail of HSCOC4JPEA_l _P3S comprising a polypeptide being at least 70%, optionally at least about S0%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence DVTLSGPQVTLLPFPCTPAPCSLCS in HSCOC4_PEA_J_P3S.
  • an isolated chimeric polypeptide encoding for HSCOC4JPEA_l JP39 comprising a first amino acid sequence being at least 90 % homologous to
  • an isolated polypeptide encoding for a tail of HSCOC4JPEA_l JP39 comprising a polypeptide being at least 70%, optionally at least about 80%>, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence VSSRGEG in HSCOC4_PEA_l_P39.
  • an isolated chimeric polypeptide encoding for HSCOC4J?EA_l JP40 comprising a first amino acid sequence being at least 90 % homologous to
  • HSCOC4JPEA_l JP40 wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.
  • an isolated polypeptide encoding for a tail of HSCOC4JPEA_l JP40 comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and pjost preferably at least about 95% homologous to the sequence AGEWTEPHFPLKGRVPGRPGEAEYGHY in HSCOC4_PEA_l JP40.
  • an isolated chimeric polypeptide encoding for HSCOC4JPEA_l JP41 comprising a first amino acid sequence being at least 90 % homologous to
  • an isolated polypeptide encoding for a tail of HSCOC4JPEA_l JP41 comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90%> and most preferably at least about 95% homologous to the sequence SGER in HSCOC4JPEA_JJP41.
  • an isolated chimeric polypeptide encoding for HSCOC4JPEA_l JP42 comprising a first amino acid sequence being at least 90 % homologous to MRLLWGLIWASSFFTLSLQKPRLLLFSPSWHLGVPLSVGVQLQDVPRGQ WKGSVFLR ⁇ PSR ⁇ NPCSPKVDFTLSSERDFALLSLQVPLKDAKSCGLHQLLRGPEVQLVAHSPWT.
  • an isolated polypeptide encoding for an edge portion of HSCOC4JPEA_l JP42 comprising an amino acid sequence being at least 70%, optionally at least about 80%>, preferably at least about 85%, more preferably at least about 90%> and most preferably at least about 95% homologous to the sequence encoding for WAPGAALGQGREGRTQAGAGLLEPAQAEPGRQLTRLHR, co ⁇ esponding to HSCOC4JPEA_l JP42.
  • an isolated polypeptide encoding for a tail of HSCOC4JPEA_l JP42 comprising a polypeptide being at least 70%, optionally at least about S0%, preferably at least about 85%, more preferably at least about 90%> and most prefej-jbly at least about 95%) homologous to the sequence VWSATQGNPLCPRY in HSCOC4 _PEA_l_P42.
  • an isolated chimeric polypeptide encoding for HUMTREFACJPEAJ2 JP8 comprising a first amino acid sequence being at least 90 %> homologous to
  • an isolated polypeptide encoding for a tail of HUMTREFACJPEA_2_P8 comprising a polypeptide being at least 70%, optionally at least about 80%), preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence WKVHLPKGEGFSSG in HIJMTREFACJPEA_2JP8.
  • an isolated chimeric polypeptide encoding for HUMOSTRO JPE A_l JPEA_1 JP21 comprising a first amino acid sequence being at least 90 % homologous to
  • an isolated polypeptide encoding for a tail of HUMOSTRO JPE A_l JPEA_1JP21 comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90%> and most preferably at least about 95 % homologous to the sequence VFLNFS in HUMOSTRO JPEA_1JPEA_1JP21.
  • an isolated chimeric polypeptide encoding for HLTMOSTROJ?EA_l JPEA_1 JP25 comprising a first amino acid sequence being at least 90 % homologous to
  • HUMOSTRO_PEA__l _PEA_1_P25 and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90%» and most preferably at least 95%> homologous to a polypeptide having the sequence H co ⁇ esponding to amino acids 32 - 32 of HUM0STR0JPEA_1JPEA_JJP25, wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.
  • HUMOSTROJPEA_J_PEA_l JP30 and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence VSIFYVFI co ⁇ esponding to amino acids 32 - 39 of HUMOSTRO_PEA_1_PEA_J_P30, wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.
  • an isolated polypeptide encoding for a tail of HUMOSTROJPEA_l JPEA_1_P30 comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence VSIFYVFI in HUMOSTRO_PEA_1_PEA_1_P30.
  • YMCQAHNSATGLNRTTVTMITNS corresponding to amino acids 1 - 319 of CEA6_HUMA ⁇ , which also co ⁇ esponds to amino acids 1 - 319 of T10888J?EA_1J?2, and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95%> homologous to a polypeptide having the sequence DWTRP co ⁇ esponding to amino acids 320 - 324 of T10888JPEA_1 JP2, wherein said first and second amino acid sequences are contiguous and in a sequential order.
  • an isolated polypeptide encoding for a tail of T 10888 JPEA_1 JP2 comprising a polypeptide being at least 70%, optionally at least about 80%>, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence DWTRP in T10888J?EA_1_P2.
  • an isolated chimeric polypeptide encoding for T10888JPEA_1 JP4 comprising a first amino acid sequence being at least 90 % homologous to
  • an isolated polypeptide encoding for a tail of T10S88JPEA_1 JP4 comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about S5%>, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence LLLSSQLWPPSASRLECWPGWL in T10888_PEA_J JP4.
  • an isolated chimeric polypeptide encoding for T108SSJPEA_1 JP4 comprising a first amino acid sequence being at least 90 % homologous to
  • an isolated polypeptide encoding for a tail of T10888JPEA_1 JP4 comprising a polypeptide being at least 70%, optionally at least about 80%>, preferably at least about 85%, more preferably at least about 90%> and most preferably at least about 95%) homologous to the sequence LLLSSQLWPPSASRLECWPGWL in T10S88_PEA_1_P4.
  • an isolated chimeric polypeptide encoding for T108SSJPEA_1 JP5 comprising a first amino acid sequence being at least 90 % homologous to
  • an isolated polypeptide encoding for a tail of T10888JPEA_1 JP5 comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence KWfflEALASHFQVESGSQRRAl ⁇ KJvFSFPTCVQGAHANPKFSPEPSQFTSADSFPLVFLFF WFCFLISHV in T10888_PEA_1 JP5.
  • T39971_P6 an isolated chimeric polypeptide encoding for T39971 JP9, comprising a first amino acid sequence being at least 90 % homologous to MAPLRPLLILALLAWNALADQESCKGRCTEGFNNDKKCQCDELCSY ⁇ QSCCTDYTAEC KPQVTRGDVFTMPEDEYTVYDDGEEK ⁇ ATVHEQVGGPSLTSDLQAQSKG ⁇ PEQTPV LKPEEEAPAPEVGASKPEG ⁇ DSRPETLHPGRPQPPAEEELCSGKPFDAFTDLK ⁇ GSLFAFR
  • PAPGHL co ⁇ esponding to amino acids 357 - 478 of VTNCJHUMAN, which also co ⁇ esponds to amino acids 326 - 447 of T39971 JP9, wherein said first and second amino acid sequences are contiguous and in a sequential order.
  • an isolated chimeric polypeptide encoding for an edge portion of T39971JP9 comprising a polypeptide having a length "n", wherein n is at least about 10 amino acids in length, optionally at least about 20 amino acids in length, preferably at least about 30 amino acids in length, more preferably at least about 40 amino acids in length and most preferably at least about 50 amino acids in length, wherein at least two amino acids comprise TS, having a structure as follows: a sequence starting from any of amino acid numbers 325-x to 325; and ending at any of amino acid numbers 326 + ((n-2) - x), in which x varies from 0 to n-2.
  • an isolated chimeric polypeptide encoding for T39971 JP1 1 comprising a first amino acid sequence being at least 90 % homologous to
  • CEGSSLSAVFEHFAMMQRDSWEDLFELLFWGRTS co ⁇ esponding to amino acids 1 - 326 of VTNCJHUMAN, which also co ⁇ esponds to amino acids 1 - 326 of T39971JP11, and a second amino acid sequence being at least 90 % homologous to
  • an isolated chimeric polypeptide encoding for an edge portion of T39971 JP11 comprising a polypeptide having a length "n", wherein n is at least about 10 amino acids in length, optionally at least about 20 amino acids in length, preferably at least about 30 amino acids in length, more preferably at least about 40 amino acids in length and most preferably at least about 50 amino acids in length, wherein at least two amino acids comprise SD, having a structure as follows: a sequence starting from any of amino acid numbers 326-x to 326; and ending at any of amino acid numbers 327 + ((n-2) - x), in which x varies from 0 to n-2.
  • DKY TIVNLRTRRVDTVDPPYPRSIAQYWLGCPAPGHL co ⁇ esponding to amino acids 442 - 478 of Q9BSH7, which also co ⁇ esponds to amino acids 327 - 363 of T39971 JP1 1, wherein said first and second amino acid sequences are contiguous and in a sequential order.
  • an isolated chimeric polypeptide encoding for an edge portion of T39971JP11 comprising a polypeptide having a length "n", wherein n is at least about 10 amino acids in length, optionally at least about 20 amino acids in length, preferably at least about 30 amino acids in length, more preferably at least about 40 amino acids in length and most preferably at least about 50 amino acids in length, wherein at least two amino acids comprise SD, having a structure as follows: a sequence starting from any of amino acid numbers 326-x to 326; and ending at any of amino acid numbers 327 + ((n-2) - x), in which x varies from 0 to n-2.
  • an isolated chimeric polypeptide encoding for T39971JP12 comprising a first amino acid sequence being at least 90 % homologous to
  • an isolated polypeptide encoding for a tail of T39971JP12 comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90%> and most preferably at least about 95%> homologous to the sequence VPGAVGQGRKHLGRV in T39971 J > 12.
  • an isolated chimeric polypeptide encoding for T39971 JP12 comprising a first amino acid sequence being at least 90 % homologous to
  • an isolated polypeptide encoding for a tail of T39971 JP12 comprising a polypeptide being at least 70%), optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95 %> homologous to the sequence VPGAVGQGRKHLGRV in T39971_P12.
  • an isolated chimeric polypeptide encoding for Z21368_PEA_J_P2 comprising a first amino acid sequence being at least 90 % homologous to
  • an isolated polypeptide encoding for a tail of Z21368JPEA_1 JP2 comprising a polypeptide being at least 70%, optionally at least about 80%>, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence PHKYSAHGRTRHFESATRTTNGAQKLSRI in Z21368_PEA_1_P2.
  • an isolated chimeric polypeptide encoding for Z21368JPEA_1 JP5 comprising a first amino acid sequence being at least 90 % homologous to
  • MKYSCCALVLAVLGT ⁇ LLGSLCSTVRSPRFRGRIQQERKNIRPNTILVLTDDQDVEL co ⁇ esponding to amino acids 1 - 57 of Q7Z2W2, which also co ⁇ esponds to amino acids 1 - 57 of Z21368J?EA_1JP5, second bridging amino acid sequence comprising A, and a third amino acid sequence being at least 90 % homologous to
  • an isolated polypeptide encoding for an edge portion of Z21368_PEA_1_P5 comprising a polypeptide having a length "n", wherein n is at least about 10 amino acids in length, optionally at least about 20 amino acids in length, preferably at least about 30 amino acids in length, more preferably at least about 40 amino acids in length and most preferably at least about 50 amino acids in length, wherein at least three amino acids comprise LAF having a structure as follows (numbering according to Z21368J?EA_1 JP5): a sequence starting from any of amino acid numbers 57-x to 57; and ending at any of amino acid numbers 59 + ((n-2) - x), in which x varies from 0 to n-2.
  • an isolated chimeric polypeptide encoding for Z2136SJPEA_J_P5 comprising a first amino acid sequence being at least 70%, optionally at least 80%>, preferably at least 85%, more preferably at 5 least 90% and most preferably at least 95% homologous to a polypeptide having the sequence MKYSCCALVLAVLGTELLGSLCSTVRSPPJHlGRIQQERKN PNIILVLTDDQDVELAFF GKYLNEYNGSYPPGWP ⁇ WLGLKNSRFYNYTVCRNGIK ⁇ INYFKMSKPJvIYPHRPVMMVTSHAAPHGPEDSAPQFSKLYPNASQmTPSYNYAPNMDK HW QYTGPMLPIH ffiFTT ⁇ LQPJOlLQTLMSVDDSVERLYNMLVETGELENTYIIYTAJ3 l o HGY ⁇ IGQFGLVKGKSMP Y
  • an 5 isolated polypeptide encoding for a head of Z21368JPEA_1 JP5 comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%>, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence MKYSCCALVLAVLGTELLGSLCST ⁇ SPPJRGRIQQERKNIRPNlILVLTDDQDVELAFF GKYL ffiYNGSYIPPGWREWLGLIKNSRFYNYTNCRNGIJ ⁇ KHGFDYAKDYFTDLITNES0 IN KMSKPsMYPHRPVMMVISHAAPHGPEDSAPQFSKLYPNASQHITPSYNY ⁇ APNMDK HWIMQYTGPMLPIHMEFTMLQRKRLQTLMSVDDSVERLYNML ⁇ TGELENTYHIYTAD HGYHIGQFGLVKGKS
  • an isolated chimeric polypeptide encoding for Z21368 JPE A_1_P5 comprising a first amino acid sequence being at least 90 %> homologous to MKYSCCALVLAVLGTELLGSLCSTVRSPRFRGRIQQERIs-NTRPNIILVLTDDQDVEL co ⁇ esponding to amino acids 1 - 57 of SUL1 JHUMAN, which also co ⁇ esponds to amino acids 1 - 57 of Z21368JPEA_1 JP5, and a second amino acid sequence being at least 90 % homologous to
  • an isolated polypeptide encoding for a tail of Z21368JPEA_1 JP16 comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence CVTVPPLSQPQIH in Z2136SJPEA_1_P16.
  • an isolated chimeric polypeptide encoding for Z21368J?EA_ 1 JP22 comprising a first amino acid sequence being at least 90 % homologous to
  • an isolated polypeptide encoding for a tail of Z21368_PEA_1JP22 comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence ARYDGDQPRCAPRPRGLSPTVF in Z2136S_PEA_1_P22.
  • an isolated chimeric polypeptide encoding for Z21368JPEA_1 JP23 comprising a first amino acid sequence being at least 90 % homologous to
  • an isolated polypeptide encoding for a tail of Z21368JPEA_1 JP23 comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence GLLHRL ⁇ H in Z21368JPEA_1JP23.
  • an isolated chimeric polypeptide encoding for Z21368JPEA_1 JP23 comprising a first amino acid sequence being at least 90 % homologous to MKYSCCALNLA ⁇ T.GTELLGSLCST ⁇ H ⁇ SPRFRGRIQQERK ⁇ IRP ⁇ IILNLTDDQDVELGSL QV ⁇ I ⁇ KTROMEHGGATFI ⁇ AFVTTPMCCPSRSSMLTGKYVFf ⁇ H ⁇ W.
  • an isolated polypeptide encoding for a tail of Z21368JPEA_1 JP23 comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%>, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence GLLHRLNH in Z21368_PEA_1 JP23.
  • an isolated chimeric polypeptide encoding for T59832JP5 comprising a first amino acid sequence being at least 90 % homologous to
  • MTLSPLLLFLPPLLLLLDVPTAAVQASPLQALDFFGNGPPVNYK co ⁇ esponding to amino acids 12 - 55 of GILT JHUMAN, which also co ⁇ esponds to amino acids 1 - 44 of T59832JP5, and a second amino acid sequence being at least 70%>, optionally at least 80%, preferably at least 85%, more preferably at least 90%) and most preferably at least 95% homologous to a polypeptide having the sequence
  • an isolated chimeric amino acids 45 - 189 of T59832JP5 wherein said first and second amino acid sequences are contiguous and in a sequential order.
  • an isolated polypeptide encoding for a tail of T59832JP5 comprising a polypeptide being at least 70%, optionally at least about 80%), preferably at least about 85%, more preferably at least
  • ECAMGDRGMQLMHANAQRTDALQPPHEYNPWVTVNG co ⁇ esponding to amino acids 12 - 223 of GELT JHUMAN, which also co ⁇ esponds to amino acids 1 - 212 of T59832JP7, and a second amino acid sequence being at least 70%>, optionally at least 80%, preferably at least 85%, more preferably at least 90%> and most preferably at least 95% homologous to a polypeptide having the sequence VPJFLALSLTXlVPWSQGWTRQRDQR co ⁇ esponding to amino acids 213 - 238 of T59832JP7, wherein said first and second amino acid sequences are contiguous and in a sequential order.
  • an isolated polypeptide encoding for a tail of T59832JP7 comprising a polypeptide being at least 70%>, optionally at least about 80%>, preferably at least about S5%>, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence VRIFLALSLTLIVPWSQGWTRQRDQR in T59832_P7.
  • an isolated chimeric polypeptide encoding for T59832JP7 comprising a first amino acid sequence being at least 90 % homologous to
  • an isolated polypeptide encoding for a tail of T59832JP7 comprising a polypeptide being at least 70%, optionally at least about 80%>, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence VRIFLALSLTLIVPWSQGWTRQRDQR in T59832_P7.
  • an isolated chimeric polypeptide encoding for T59832JP7 comprising a first amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence MTLSPLLLFLPPLLLLLDVPTAAVQASPLQALDFFGNGPPVNYKTGNLYLRGPLKKSNA PLVNVTLYYEALCGGCRAFLIRELFPTWLLV co ⁇ esponding to amino acids 1 - 90 of T59832JP7, and a second amino acid sequence being at least 90 % homologous to MEI NVTL YGNAQEQNVSGRWEFXCQHGEEECK-FNKVEACVLDELDMELAFLT C MEEFEDMERSLPLCLQLYAPGLSPDTIMECAMGDRGMQLMHANAQRTDALQPPHEYV PWVTNNGVRIFLALSLTLr
  • an isolated polypeptide encoding for a head of T59832JP7 comprising a polypeptide being at least 10%, optionally at least about 80%>, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence MTLSPLLLFLPPLLLLLDVPTAAVQASPLQALDFFGNGPPVNYKTGNLYLRGPLKKSNA PLVNVTLYYEALCGGCRAFLIRELFPTWLLV of T59832JP7.
  • an isolated chimeric polypeptide encoding for T59832JP7 comprising a first amino acid sequence being at least 90 % homologous to
  • ECAMGDRGMQLMHANAQRTDALQPPHEYVPWVTVNG co ⁇ esponding to amino acids 1 - 212 of Q8WU77, which also co ⁇ esponds to amino acids 1 - 212 of T59832JP7, and a second amino acid sequence being at least 70%), optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence VRIFLALSLTLIVPWSQGWTRQRDQR co ⁇ esponding to amino acids 213 - 238 of T59832JP7, wherein said first and second amino acid sequences are contiguous and in a sequential order.
  • an isolated polypeptide encoding for a tail of T59832JP7 comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90%) and most preferably at least about 95 % homologous to the sequence VRTFLALSLTL ⁇ VPWSQGWTRQRDQR in T59832JP7.
  • an isolated chimeric polypeptide encoding for T59832JP9 comprising a first amino acid sequence being at least 90 %» homologous to
  • ECAMGDRGMQLMHANAQRTDALQPPHE co ⁇ esponding to amino acids 12 - 21 ' 4 of GfLTJHUMAN, which also co ⁇ esponds to amino acids 1 - 203 of T59832JP9, and a second amino acid sequence being at least 70%, optionally at least 80%>, preferably at least 85%, more preferably at least 90%) and most preferably at least 95% homologous to a polypeptide having the sequence NPWKIRPSSLPLSASCTRARSRMSALPQPAPSGVFASSDGR co ⁇ esponding to amino acids 204 - 244 of T59832JP9, wherein said first and second amino acid sequences are contiguous and in a sequential order.
  • an isolated polypeptide encoding for a tail of T59832JP9 comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence NPWKXRPSSLPLSASCTRARSRMSALPQPAPSGVFASSDGR in T59832_P9.
  • an isolated chimeric polypeptide encoding for T59832JP9 comprising a first amino acid sequence being at least 90 % homologous to MTLSPLLLFLPPLLLLLDVPTAAVQASPLQALDFFGNGPPVNYKTGNLYLRGPLKKSNA PLVNVTLYYEALCGGCRAFLIRELFPTWLLVMEILNNTLNPYGNAQEQNVSGRWEFKC QHGEEECKFNKVEACVLDELDMELAFLTIVCMEEFEDMERSLPLCLQLYAPGLSPDTIM ECAMGDRGMQLMHANAQRTDALQPPHE co ⁇ esponding to amino acids 1 - 203 of BAC98466, which also co ⁇ esponds to amino acids 1 - 203 of T59832JP9, and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%), more preferably at least 90% and most preferably at least 95% homologous
  • an isolated polypeptide encoding for a tail of T59832JP9 comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95%> homologous to the sequence NPWIORPSSLPLSASCTRARSRMSALPQPAPSGVFASSDGR in T59832_P9.
  • an isolated chimeric polypeptide encoding for T59832JP9 comprising a first amino acid sequence being at least 70%, optionally at least S0%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence MTLSPLLLFLPPLLLLLDVPTAAVQASPLQALDFFGNGPPVN ⁇ KTGNLYLRGPLKKSNA PLVNVTLYYEALCGGCRAFL ⁇ RELFPTWLLV co ⁇ esponding to amino acids 1 - 90 of T59832_P9, second amino acid sequence being at least 90 % homologous to MEILNVTL VPYGNAQEQNVSGRWEFKCQHGEEECKFNK VE AC VLDELDMELAFLTI VC MEEFEDMERSLPLCLQLYAPGLSPDT ⁇ MECAMGDRGMQLMHANAQRTDALQPPHE co ⁇ esponding to amino acids 1 - 90 of T59832_P9, second amino acid sequence being at least
  • a third amino acid sequence being at least 70%, optionally at least S0%, preferably at least 85%), more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence
  • an isolated polypeptide encoding for a head of T59832JP9 comprising a polypeptide being at least 70%), optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence MTLSPLLLFLPPLLLLLDVPTAAVQASPLQALDFFGNGPPVN TvTGNLYLRGPLKKSNA PLVNVTLYYEALCGGCRAFLIRELFPTWLLV of T59832_P9.
  • an isolated polypeptide encoding for a tail of T59832JP9 comprising a polypeptide being at least 70%), optionally at least about S0%>, preferably at least about 85%, more preferably at least about 90%) and most preferably at least about 95%> homologous to the sequence NPWKXRPSSLPLSASCTRARSRMSALPQPAPSGVFASSDGR in T59832JP9.
  • an isolated chimeric polypeptide encoding for T59832JP9 comprising a first amino acid sequence being at least 90 % homologous to
  • Q8WLI77 which also co ⁇ esponds to amino acids 1 - 203 of T59832JP9, and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90%) and most preferably at least 95% homologous to a polypeptide having the sequence NPWKIRPSSLPLSASCTRARSRMSALPQPAPSGVFASSDGR co ⁇ esponding to amino acids 204 - 244 of T59832JP9, wherein said first and second amino acid sequences are contiguous and in a sequential order.
  • an isolated polypeptide encoding for a tail of T59832JP9 comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90%) and most preferably at least about 95% homologous to the sequence
  • an isolated chimeric polypeptide encoding for T59832JP12 comprising a first amino acid sequence being at least 90 % homologous to MTLSPLLLFLPPLLLLLDVPTAAVQASPLQALDFFGNGPPVNYKTGNLYLRGPLKKSNA PLVNVTLYYEALCGGCP ⁇ FL ⁇ v ⁇ LFPTWLLVMEILN ⁇ TLVPYGNAQEQNVSGRWEFKC QHGEEECKFNKVE co ⁇ esponding to amino acids 12 - 141 of GELT JHUMAN, which also conesponds to amino acids 1 - 130 of T59832JP12, and a second amino acid sequence being at least 90 % homologous to CLQLYAPGLSPDTLMECAMGDRGMQLMHANAQRTDALQPPHEYVPWVTVNGKP
  • an isolated chimeric polypeptide encoding for an edge portion of T59832JP12 comprising a polypeptide having a length "n", wherein n is at least about 10 amino acids in length, optionally at least about 20 amino acids in length, preferably at least about 30 amino acids in length, more preferably at least about 40 amino acids in length and most preferably at least about 50 amino acids in length, wherein at least two amino acids comprise EC, having a structure as follows: a sequence starting from any of amino acid numbers 130-x to 130; and ending at any of amino acid numbers 131+ ((n-2) - x), in which x varies from 0 to n-2.
  • an isolated chimeric polypeptide encoding for T59832JP12 comprising a first amino acid sequence being at least 10%, optionally at least 80%>, preferably at least 85%, more preferably at least 90%) and most preferably at least 95% homologous to a polypeptide having the sequence MTLSPLLLFLPPLLLLLDWTAAVQASPLQALDFFGNGPPVN T TGNLYLRGPLKKSNA PLVNVTLYYEALCGGCRAFLIRELFPTWLLV co ⁇ esponding to amino acids 1 - 90 of T59832JP12, second amino acid sequence being at least 90 % homologous to MEILNVTLNPYGNAQEQNVSGRWEFKCQHGEEECKFNKVE co ⁇ esponding to amino acids 1 - 40 of BAC85622, which also co ⁇ esponds to amino acids 91 - 130 of T59832JP12, third amino acid sequence being at least 90 %
  • CLQLYAPGLSPDTIMECAMGDRGMQLMHANAQRTDALQPPHEYVPWVTVNG co ⁇ esponding to amino acids 72 - 122 of BAC85622, which also co ⁇ esponds to amino acids 131 - 181 of T59832JP12, and a fourth amino acid sequence being at least 70%, optionally at least 80%), preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence
  • an isolated polypeptide encoding for a head of T59832JP12 comprising a polypeptide being at least 70%, optionally at least about 80%), preferably at least about 85%, more preferably at least about 90%) and most preferably at least about 95%) homologous to the sequence
  • an isolated chimeric polypeptide encoding for an edge portion of T59832JP12 comprising a polypeptide having a length "n", wherein n is at least about 10 amino acids in length, optionally at least about 20 amino acids in length, preferably at least about 30 amino acids in length, more preferably at least about 40 amino acids in length and most preferably at least about 50 amino acids in length, wherein at least two amino acids comprise EC, having a structure as follows: a sequence starting from any of amino acid numbers 130-x to 130; and ending at any of amino acid numbers 131+ ((n-2) - x), in which x varies from 0 to n-2.
  • an isolated polypeptide encoding for a tail of T59832JP12 comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90%) and most preferably at least about 95% homologous to the sequence
  • an isolated chimeric polypeptide encoding for T59832JP12 comprising a first amino acid sequence being at least 90 % homologous to MTLSPLLLFLPPLLLLLDVPTAAVQASPLQALDFFGNGPPVN ⁇ T TGNLYLRGPLKKSNA PLVNVTLY ⁇ ALCGGCRAFLE ELFPTWLLVMEILNVTLNPYGNAQEQNVSGRWEFKC QHGEEECKFNKVE conesponding to amino acids 1 - 130 of Q8WU77, which also co ⁇ esponds to amino acids 1 - 130 of T59832 JP 12, and a second amino acid sequence being at least 90 % homologous to CLQLYAPGLSPDT ⁇ MECAMGDRGMQLMHANAQRTDALQPPHEYVPWVTVNGKPLED
  • QTQLLTLVCQLYQGKKPDVCPSSTSSLRSVCFK co ⁇ esponding to amino acids 162 - 250 of Q8WU77, which also co ⁇ esponds to amino acids 131 - 219 of T59832JP12, wherein said first and second amino acid sequences are contiguous and in a sequential order.
  • an isolated chimeric polypeptide encoding for an edge portion of T59832JP12 comprising a polypeptide having a length "n", wherein n is at least about 10 amino acids in length, optionally at least about 20 amino acids in length, preferably at least about 30 amino acids in length, more preferably at least about 40 amino acids in length and most preferably at least about 50 amino acids in length, wherein at least two amino acids comprise EC, having a structure as follows: a sequence starting from any of amino acid numbers 130-x to 130; and ending at any of amino acid numbers 131+ ((n-2) - x), in which x varies from 0 to n-2.
  • an isolated chimeric polypeptide encoding for T59832J 18, comprising a first amino acid sequence being at least 90 % homologous to MTLSPLLLFLPPLLLLLDVPTAAVQASPLQALDFFGNGPPVNYK co ⁇ esponding to amino acids 12 - 55 of GILT JHUMAN, which also co ⁇ esponds to amino acids 1 - 44 of T59832JP18, and a second amino acid sequence being at least 90 %> homologous to
  • an isolated chimeric polypeptide encoding for an edge portion of T59832JP18 comprising a polypeptide having a length "n", wherein n is at least about 10 amino acids in length, optionally at least about 20 amino acids in length, preferably at least about 30 amino acids in length, more preferably at least about 40 amino acids in length and most preferably at least about 50 amino acids in length, wherein at least two amino acids comprise KC, having a structure as follows: a sequence starting from any of amino acid numbers 44-x to 44; and ending at any of amino acid numbers 45+ ((n-2) - x), in which x varies from 0 to n-2.
  • an isolated chimeric polypeptide encoding for T59832JP1S comprising a first amino acid sequence being at least 90 % homologous to
  • an isolated chimeric polypeptide encoding for an edge portion of T59832JP18 comprising a polypeptide having a length "n", wherein n is at least about 10 amino acids in length, optionally at least about 20 amino acids in length, preferably at least about 30 amino acids in length, more preferably at least about 40 amino acids in length and most preferably at least about 50 amino acids in length, wherein at least two amino acids comprise KC, having a structure as follows: a sequence starting from any of amino acid numbers 44-x to 44; and ending at any of amino acid numbers 45+ ((n-2) - x), in which x varies from 0 to n-2.
  • an isolated chimeric polypeptide encoding for T59832JP18 comprising a first amino acid sequence being at least 90 % homologous to
  • an isolated chimeric polypeptide encoding for an edge portion of T59832JP18 comprising a polypeptide having a length "n", wherein n is at least about 10 amino acids in length, optionally at least about 20 amino acids in length, preferably at least about 30 amino acids in length, more preferably at least about 40 amino acids in length and most preferably at least about 50 amino acids in length, wherein at least two amino acids comprise KC, having a structure as follows: a sequence starting from any of amino acid numbers 44-x to 44; and ending at any of amino acid numbers 45+ ((n-2) - x), in which x varies from 0 to n-2.
  • an isolated chimeric polypeptide encoding for HUMGRP5EJP4 comprising a first amino acid sequence being at least 90 % homologous to MRGSELPLVLLALVLCLAPRGPAVPLPAGGGTNLTKMYPRGNIHWAVGHLMGKKSTG ESSSVSERGSLKQQLREYIRWEEA, RNLLGLEAKENRNHQPPQPKALGNQQPSWDSED SSNFKDVGSKGK co ⁇ esponding to amino acids 1 - 127 of GRPJHUMAN, which also co ⁇ esponds to amino acids 1 - 127 of HUMGRP5EJP4, and a second amino acid sequence being at least 90 %> homologous to GSQREGRNPQLNQQ co ⁇ esponding to amino acids 135 - 148 of GRPJHLTMAN, which also co ⁇ esponds to amino acids 128 - 141 of HUMGRP5E
  • an isolated chimeric polypeptide encoding for HUMGRP5EJP5 comprising a first amino acid sequence being at least 90 % homologous to MRGSELPLVLLALVLCLAPRGRA LPAGGGTVLTKMYPRGNHWAVGHLMGKKSTG ESSSVSERGSLKQQLREYIRWEEAARNLLGLEEAKENRNHQPPQPKALGNQQPSWDSED SSNFKDVGSKGK co ⁇ esponding to amino acids 1 - 127 of GRP JHUMAN, which also co ⁇ esponds to amino acids 1 - 127 of HUMGRP5EJP5, and a second amino acid sequence being at least 70%, optionally at least 80%>, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence DSLLQVLNVKEGTPS co ⁇ esponding to amino acids 128 - 142
  • an isolated polypeptide encoding for a tail of HUMGRP5EJP5 comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90%) and most preferably at least about 95% homologous to the sequence DSLLQVLNVKEGTPS in HUMGRP5E_P5.
  • an isolated chimeric polypeptide encoding for AA155578J?EA_1 JP4 comprising a first amino acid sequence being at least 90 % homobgous to
  • KLKA JHUMAN which also co ⁇ esponds to amino acids 1 - 29 of AA155578_PEA_1JP6, and a second amino acid sequence being at least 90 % homologous to
  • an isolated chimeric polypeptide encoding for AA155578JPEA_1_P8, comprising a first amino acid sequence being at least 90 % homologous to MRAPHLHLSAASGARALAKLLPLLMAQLW co ⁇ esponding to amino acids 1 - 29 of KLKA JHUMAN, which also co ⁇ esponds to amino acids 1 - 29 of AA155578_PEA_1 JP8, and a second amino acid sequence being at least 70%, optionally at least 80%), preferably at least 85%>, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence GHCGLE co ⁇ esponding to amino acids 30 - 35 of AA155578JPEA_1 JP8, wherein said first and second amino acid sequences are contiguous and in a sequential order.
  • an isolated chimeric polypeptide encoding for AA 155578 J?EA_1_P9 comprising a first amino acid sequence being at least 90 % homologous to MRAPHLHLSAASGARALAKLLPLLMAQLWAAEAALLPQNDTRLDPEAYGAPCARGSQ PWQVSLFNGLSFHCAGVLVDQSWVLTAAHCGNK co ⁇ esponding to amino acids 1 - 90 of KLKA JHUMAN, which also co ⁇ esponds to amino acids 1 - 90 of AA155578_PEA_1_P9.
  • an isolated chimeric polypeptide encoding for HSENA78_P2 comprising a first amino acid sequence being at least 90 % homologous to
  • an isolated chimeric polypeptide encoding for T94936JPEA_1_P2 comprising a first amino acid sequence being at least 90 % homologous to MMLHSALGLCLLLVTVSSNLAIAIKKEKRPPQTLSRGWGDDITWNQTYEEGLFYAQKS KLKPLMVIHHLEDCQYSQALKXWAQ ⁇ EEIQEMAQ ⁇ I ⁇ IML
  • VPRIMFVDPSLTVRADIAGRYS ⁇ RLYTYEPRDLPL co ⁇ esponding to amino acids 1 - 150 of Q8TD06, which also co ⁇ esponds to amino acids 1 - 150 of T94936JPEA_1JP2.
  • an isolated chimeric polypeptide encoding for T94936_PEA_1_P3 comprising a first amino acid sequence being at least 90 % homologous to
  • an isolated chimeric polypeptide encoding for Z41644JPEA_1 JP10 comprising a first amino acid sequence being at least 90 %> homologous to

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)

Abstract
EP05718182A 2004-01-27 2005-01-27 Nouvelles sequences nucelotidiques et d'acides amines, et leurs dosage et procedes d'utilisation pour le diagnostic du cancer du sein Withdrawn EP1732943A4 (fr)

Applications Claiming Priority (25)

Application Number Priority Date Filing Date Title
US53912804P 2004-01-27 2004-01-27
US53912904P 2004-01-27 2004-01-27
US62100404P 2004-10-22 2004-10-22
US62097404P 2004-10-22 2004-10-22
US62091604P 2004-10-22 2004-10-22
US62087404P 2004-10-22 2004-10-22
US62092404P 2004-10-22 2004-10-22
US62091804P 2004-10-22 2004-10-22
US62097504P 2004-10-22 2004-10-22
US62065604P 2004-10-22 2004-10-22
US62085304P 2004-10-22 2004-10-22
US62091704P 2004-10-22 2004-10-22
US62113104P 2004-10-25 2004-10-25
US62012304P 2004-11-17 2004-11-17
US62813404P 2004-11-17 2004-11-17
US62823104P 2004-11-17 2004-11-17
US62811104P 2004-11-17 2004-11-17
US62815604P 2004-11-17 2004-11-17
US62817804P 2004-11-17 2004-11-17
US62814504P 2004-11-17 2004-11-17
US62810104P 2004-11-17 2004-11-17
US62816704P 2004-11-17 2004-11-17
US62825104P 2004-11-17 2004-11-17
US62811204P 2004-11-17 2004-11-17
PCT/IB2005/000433 WO2005072050A2 (fr) 2004-01-27 2005-01-27 Nouvelles sequences nucleotidiques et d'acides amines, et leurs dosages et procedes d'utilisation pour le diagnostic du cancer du sein

Publications (2)

Publication Number Publication Date
EP1732943A2 true EP1732943A2 (fr) 2006-12-20
EP1732943A4 EP1732943A4 (fr) 2011-01-12

Family

ID=37398553

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05718182A Withdrawn EP1732943A4 (fr) 2004-01-27 2005-01-27 Nouvelles sequences nucelotidiques et d'acides amines, et leurs dosage et procedes d'utilisation pour le diagnostic du cancer du sein

Country Status (1)

Country Link
EP (1) EP1732943A4 (fr)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030100723A1 (en) * 2000-07-26 2003-05-29 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2003004989A2 (fr) * 2001-06-21 2003-01-16 Millennium Pharmaceuticals, Inc. Compositions, trousses, et procedes d'identification, d'evaluation, de prevention, et de therapie pour le cancer du sein

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL [Online] XP002611793, retrieved from ebi accession no. EM_NEW:GX181231 Database accession no. GX181231 & US 2003/124128 A1 (LILLIE JAMES [US] ET AL LILLIE JAMES [US] ET AL) 3 July 2003 (2003-07-03) *
DATABASE EMBL [Online] XP002611794, retrieved from ebi accession no. EM_PAT:GX181230 Database accession no. GX181230 *
DATABASE Geneseq [Online] 29 January 2004 (2004-01-29), XP002611795, retrieved from EBI accession no. GSP:ADE05342 Database accession no. ADE05342 & US 2003/100723 A1 (BAKER KEVIN P [US] ET AL) 29 May 2003 (2003-05-29) *
FLETCHER G C ET AL: "hAG-2 and hAG-3, human homologues of genes involved in differentiation, are associated with oestrogen receptor-positive breast tumours and interact with metastasis gene C4.4a and dystroglycan", BRITISH JOURNAL OF CANCER 20030224 GB LNKD- DOI:10.1038/SJ.BJC.6600740, vol. 88, no. 4, 24 February 2003 (2003-02-24), pages 579-585, XP002611796, ISSN: 0007-0920 *

Also Published As

Publication number Publication date
EP1732943A4 (fr) 2011-01-12

Similar Documents

Publication Publication Date Title
US7368548B2 (en) Nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of prostate cancer
US20060046257A1 (en) Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of lung cancer
EP0939824A1 (fr) Reactifs et procedes pour le depistage de pathologies mammaires
WO2006090389A2 (fr) Nouveaux marqueurs diagnostiques, en particulier pour l'imagerie in vivo, et dosage et procedes d'utilisation associes
US7528243B2 (en) Nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of breast cancer
US20060263786A1 (en) Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of colon cancer
WO2010061393A1 (fr) Séquences d'acides aminés et de nucléotides de variants de he4 et leurs procédés d'utilisation
US8216792B2 (en) Compositions and methods for detection and treatment of proliferative abnormalities associated with overexpression of human transketolase like-1 gene
WO2005072050A2 (fr) Nouvelles sequences nucleotidiques et d'acides amines, et leurs dosages et procedes d'utilisation pour le diagnostic du cancer du sein
US6544742B1 (en) Detection of genes regulated by EGF in breast cancer
EP1721257A2 (fr) Expression differentielle de marqueurs dans le cancer de l'ovaire
EP1774046A2 (fr) Nouvelles sequences d'aminoacides et de nucleotides, et dosages et methodes d'utilisation afferentes dans le diagnostic du cancer du poumon
EP1749025A2 (fr) Nouveaux nucleotides et sequences d'acides amines, et leurs dosages et procedes d'utilisation pour le diagnostic du cancer du colon
EP1732943A2 (fr) Nouvelles sequences nucelotidiques et d'acides amines, et leurs dosage et procedes d'utilisation pour le diagnostic du cancer du sein
US20060275314A1 (en) Transmembrane protein differentially expressed in cancer
WO2006043271A1 (fr) Nouvelles sequences d'acides amines et sequences nucleotidiques et methodes d'utilisation de celles-ci pour le diagnostic
WO2006021874A2 (fr) Nouvelles sequences de nucleotides et d'acides amines; essais et methodes d'utilisation pour le diagnostic du cancer de a la prostate
EP1735468A2 (fr) Nouvelles sequences de nucleotides et d'acides amines; essais et methodes d'utilisation pour le diagnostic du cancer de a la prostate
WO2005107364A9 (fr) Nouvelles sequences de nucleotides et d'acides amines, et leurs dosages et procedes d'utilisation pour le diagnostic
EP1996721A2 (fr) Nouvelles séquences de nucléotides et d'acides aminés et leur procédés d'utilisation dans le cadre d'un diagnostic
JP2007520217A (ja) 新規ヌクレオチドおよびアミノ酸配列、ならびにそれを用いた乳癌診断のためのアッセイおよび使用方法
AU2005276208A1 (en) Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of prostate cancer
HK1078615A (en) Compositions and methods for detection and treatment of proliferative abnormalities associated with overexpression of human transketolase like-1 gene
CA2554623A1 (fr) Nouveaux nucleotides et sequences d'acides amines, et leurs dosages et procedes d'utilisation pour le diagnostic du cancer du colon

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060825

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR LV MK YU

RIN1 Information on inventor provided before grant (corrected)

Inventor name: SHKLAR, MAXIM

Inventor name: KEREN, NAOMI

Inventor name: SHEMESH, RONEN

Inventor name: SAMEAH-GREENWALD, SHIRLEY

Inventor name: WALACH, SHIRA

Inventor name: AYALON-SOFER, MICHAL

Inventor name: SELLA-TAVOR, OSNAT

Inventor name: NOVIK, AMIT

Inventor name: DIBER, ALEXANDER

Inventor name: AKIVA, PINCHAS

Inventor name: LEVINE, ZURIT

Inventor name: POLLOCK, SARAH

Inventor name: SOREK, ROTEM

Inventor name: DAHARY, DVIR

Inventor name: TOPORIK, AMIR

DAX Request for extension of the european patent (deleted)
RIN1 Information on inventor provided before grant (corrected)

Inventor name: SHKLAR, MAXIM

Inventor name: KEREN, NAOMI

Inventor name: SHEMESH, RONEN

Inventor name: SAMEAH-GREENWALD, SHIRLEY

Inventor name: WALACH, SHIRA

Inventor name: AYALON-SOFER, MICHAL

Inventor name: SELLA-TAVOR, OSNAT

Inventor name: NOVIK, AMIT

Inventor name: DIBER, ALEXANDER

Inventor name: AKIVA, PINCHAS

Inventor name: LEVINE, ZURIT

Inventor name: POLLOCK, SARAH

Inventor name: SOREK, ROTEM

Inventor name: DAHARY, DVIR

Inventor name: TOPORIK, AMIR

PUAK Availability of information related to the publication of the international search report

Free format text: ORIGINAL CODE: 0009015

RIC1 Information provided on ipc code assigned before grant

Ipc: C07H 21/02 20060101ALI20100526BHEP

Ipc: C12Q 1/68 20060101ALI20100526BHEP

Ipc: G01N 33/53 20060101AFI20100526BHEP

RIC1 Information provided on ipc code assigned before grant

Ipc: C12Q 1/68 20060101ALI20101201BHEP

Ipc: C07K 14/47 20060101ALI20101201BHEP

Ipc: G01N 33/574 20060101ALI20101201BHEP

Ipc: G06F 19/00 20110101ALI20101201BHEP

Ipc: G01N 33/48 20060101AFI20101201BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20101210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20110308